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Rotavirus morphogenesis starts in intracellular inclusion bodies called viroplasms, 
where synthesis of the11 dsRNA genome segments and their packaging in new viral 
particles take place. RNA replication is mediated by several viral proteins, of which 
VP1, the RNA-dependent RNA polymerase, and VP2, the core scaffolding protein, 
were shown to be sufficient to provide replicase activity in vitro. In vivo, however, 
viral replication complexes also contain the nonstructural proteins NSP2 and NSP5, 
which were shown to be essential for replication, to interact with each other and to 
form viroplasm-like structures (VLS) when coexpressed in uninfected cells.  
In order to gain a better understanding of the intermediates formed during viral 
replication, this work focused on the interactions of NSP5 with VP1, VP2 and NSP2.  
We constructed a tagged form of VP1 and by coimmunoprecipitation experiments 
we demonstrated that VP1 and NSP5 interact in virus-infected cells as well as in the 
absence of other viral proteins or viral RNA in cotransfected cells. Using deletion 
mutants of NSP5 or different fragments of NSP5 fused to EGFP, we identified the 48 
C-terminal amino acids as the region essential for interaction with VP1. On the other 
hand, removal of the C-terminal 15 amino acids from tagged VP1 resulted in a less 
efficient coimmunoprecipitation with NSP5, suggesting an involvement of the C-
terminus of VP1. Interaction of NSP5 with VP2 was investigated by coexpression of 
the two proteins in uninfected cells, which resulted in a strong hyperphosphorylation 
of NSP5 and in the formation of VLS, that we named VLS(VP2i) to distinguish them 
from those induced by NSP2, here designated as VLS(NSP2i). VLS(VP2i) were shown 
to assemble independently of the phosphorylation degree of NSP5 and to recruit the 





layer of the virion). Attempts to coimmunoprecipitate NSP5 and VP2 failed both from 
infected and cotransfected cells.  
Tagged VP1 was found to localize in VLS (both VP2i and NSP2i) and in viroplasms, 
and to be able to replace wild-type VP1 structurally by being incorporated into 
progeny viral particles. Coexpression of different combinations of tagged VP1, 
NSP5, NSP2 and VP2 showed that the interaction of VP1 with NSP5 is not affected 
by the other viral proteins and is stronger than the interaction with NSP2. In addition, 
an inhibitory effect of VP1 on the levels of NSP5 hyperphosphorylation induced by 
both NSP2 and VP2 was observed. 
Altogether, these data confirmed an important role for NSP5 in replication, related 
with the interactions with the two structural proteins essentially involved in viral 
genome synthesis, and suggested that NSP5 plays a key role in architectural 
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Rotavirus was identified as a cause of human acute gastroenteritis (AGE) in 1973, 
when it was found in duodenal biopsies from children with acute non-bacterial 
gastroenteritis (25, 99), and then it has been recognized as the major etiologic 
agent of gastroenteritis in infants and young children worldwide. According to data 
collected until 2006, rotavirus is responsible for 500,000-600,000 deaths every 
year, 80% of which occur in developing countries, and in addition represents a 
significant cause of morbidity in developed countries (203). Two oral, live-attenuated 
vaccines have been shown to be effective and safe in several clinical trials and were 
licensed by many countries worldwide (73, 91). Several post-marketing surveillance 
studies are now under way to monitor the impact of these vaccines. Moreover, since 
human rotaviruses exhibit a huge genomic and antigenic diversity and since the 
pressure of anti-rotavirus vaccine-specific antibodies might select novel strains, many 
studies are aimed at evaluating the present geographical distribution of the different 
strains and its variations over time (73). 
Studies on the molecular biology of rotavirus have so far led to a large but not 
exhaustive knowledge of the mechanisms, by which the virus replicates inside the host 
cell. One of the main limits is the lack of a universal reverse genetics system that 
enables to manipulate the virus genome and to identify roles and functions of the 
different viral proteins. In fact, for several of them the essential involvement in viral 
replication has been clearly demonstrated, but the exact function remains unknown, 






1. VIRUS CLASSIFICATION 
 
Rotaviruses are classified as a genus within the family Reoviridae, which includes 
non-enveloped viruses with segmented, double-stranded RNA (dsRNA) genomes. The 
name is derived from Latin “rota”, meaning “wheel”, and is due to the wheel-like 
appearance of the virion observed by electron microscopy. A triple-layered 
icosahedral protein capsid encloses 11 genome segments (91).  
Rotaviruses are classified serologically into groups: viruses sharing cross-reacting 
antigens detectable by serologic tests with different monoclonal and polyclonal 
antibodies against VP6 (the protein forming the middle layer) belong to the same 
group. Five groups have been firmly established (A to E) and two more groups (F, G) 
are likely to exist; group A rotaviruses are those of major medical interest. Viruses 
within group A are classified further either into serotypes by cross-neutralization 
studies or into genotypes by sequence comparison. Serotypes are defined in a binary 
classification system by VP4 and VP7, which are the components of the external layer 
and are targets of neutralizing antibodies: serotypes determined by VP7 are termed 
G (which stands for glycoprotein) and those defined by VP4 are named P (which 
stands for protease-sensitive protein). Genotypes are based on identities between 
sequences of cognate genome segments. So far, 16 different G genotypes and 27 P 
genotypes have been detected. Whilst for G serotypes and G genotypes the 
correlation is practically complete, there is no concordance between P serotypes and 
P genotypes and they are still designated separately (the serotype in open Arabic 
numbers and letters and the genotype in Arabic numbers in squared brackets: for 
example, the human Wa strain is classified as G1P1A[8]) (91). A new classification 





segments and phylogenetic analyses, which allow to identify in a comprehensive 
fashion distinct genotypes and reassortment events (175, 176). 
 




Structural studies using cryoelectron microscopy and computer image 
reconstruction have provided a description of the virion as an icosahedral particle of 
75nm diameter and consisting of three concentric capsid protein layers (235, 300). 
The complete viral particle (= the infectious virion) is called triple-layered particle (TLP), 
a particle where the outer layer is missing is named double-layered particle (DLP) and 
a subviral particle containing only the innermost layer is designated as a single-
layered particle or “core”. The genome consisting of 11 segments of double-strand 
RNA (dsRNA) is packaged within the inner layer, together with two proteins involved 
in transcription and genome replication: the RNA-dependent RNA polymerase (RdRp), 
VP1, and the capping enzyme, VP3. The inner layer is formed by 120 molecules of 
VP2, the middle layer by 260 trimers of VP6 and the outer layer by 780 molecules 
(260 trimers) of VP7 and 60 trimers of VP4 (Fig. 1) (91). The entire structure has a left 
handed T=13 icosahedral symmetry and is perforated by 132 aqueous channels of 
three types (I-III). The type I channels play an important role in viral transcription as 
through them the newly formed messenger RNA (mRNA) exits into the cytoplasm. A 
detailed description of the virion 3D structure and of the genome organization is 









2.2. SPATIAL ORGANIZATION OF THE TRIPLE-LAYERED PARTICLE 
 
The outer layer of the TLP is formed by the major protein VP7, which is 
uniformly distributed giving rise to a smooth outer surface. The 780 molecules of VP7, 
organized as trimers, form a T=13l (l for levo) icosahedral lattice defining the different 
types of aqueous channels (235). Sixty VP4 projections are anchored near the type II 
channels surrounding each 5-fold vertex (232, 299). The VP4 spikes protrude for 
about 100-120Å and present a bi-lobed head at the distal end (232, 300). Recent 
structural studies suggest that the each spike is a VP4 trimer, in which two VP4 
molecules are associated and form the visible spike and the third VP4 molecule is 
flopping and not visible by cryo-EM (see Fig. 5 in chapter 3) (81). VP4 interacts with 
both VP7 and the middle layer protein VP6 and through these interactions plays an 
important role in maintaining the precise geometric arrangements between the outer 
and the  middle layer (299). 
FIG. 1:  cut-away view of the rotavirus TLP 
showing the outer layer (VP7 in yellow and 
VP4 in red), the middle layer (VP6 in blue) 
and the inner layer (VP2 in green) surrounding 
the enzymes VP1 and VP3 (in red), which are 
anchored to the inside of the VP2 layer at the 





The intermediate layer is composed of 780 VP6 polypeptides organized in 
260 trimers on a T=13 lattice, which produce the typical bristle-like structure of DLPs 
(235, 300) (Fig. 2). VP6 trimers contain conserved peptides for interactions with the 
inner layer protein VP2 on the inside and with VP7 and VP4 at the outside. While the 
lateral interactions between VP6 trimers are not sufficient to make a closed 
icosahedral structure, the interactions with VP2 drive the assembly of correctly sized 
rotavirus particles (48, 174).  The arrangements of the VP6 trimers and their contacts 
with the VP7 trimers are such that the aqueous channels in the outer and in the middle 
layers lye in register; however, VP7 induces a slight displacement of the VP6 trimers 
flanking the 5-fold axis, which is responsible for the different diameter of the type I 
channels in the two layers (156, 162). 
The inner layer is a thin, relatively smooth spherical structure formed by 120 
molecules of VP2 assembling to 60 asimmetric dimers, which are arranged in a T=1 
icosahedral simmetry (160, 234). Since VP2 is the only protein capable to form 
stable virus-like particles when expressed alone in insect cells or also with various 
combinations of VP6, VP4 and VP7 (62), it has been considered the rotavirus 
scaffolding protein (62, 153). Although VP2 forms a relatively smooth shell, a small 
portion extends further inward at the 5-fold axes to form a pentagonal structure (234) 
(Fig. 2). Small pores surrounding the 5-fold axes pass through the VP2 layer 
connecting the core environment with the outside (233, 234). 
The aqueous channels are classified in three types based on their position on 
the icosahedral structure (235). All channels are about 55Å wide at the outer 
surface, with the exception of type I channels that have a narrower opening (about 
40Å), constrict then further and widen again to reach the maximum width in proximity 
of the inner shell (235). Their depth through the two outer shells is about 140Å (235). 





icosahedral 5-fold axes, suggesting an important role for these channels in viral 
transcription (159). 
Inside the core, positioned at each of the 12 pentameric edges of the VP2 
lattice, there are complexes formed by one molecule of VP1 and one of VP3, which 
means that 12 copies of VP1 and VP3 are contained in each viral particle (234). 
Even if the exact position of the genome segments has not been determined yet, the 
dsRNA genome was visualized as an ordered dodecahedral structure, in which the 





FIG. 2:  Structural organization of RNA inside rotavirus. a) cut-away view of the rotavirus DLP 
showing internal organization: VP6 is represented in shades of blue, VP2 in shades of green; the 
VP1-VP3 complex at the 5-fold axes is shown in red and portions of VP2 at the 5-fold in green. The 
dodecahedral shell of the ordered RNA, shown also separately in b), is represented in yellow. 





2.3. THE VIRAL GENOME 
 
Rotavirus genome consists of eleven segments of dsRNA, each encoding one 
protein, with the exception of segment 11 of some strains that encodes two (NSP5 
and NSP6). The RNA segments can be extracted from purified or semipurified virus 
and resolved by polyacrylamide gel electrophoresis (PAGE), showing a migration 
pattern of eleven different bands (Fig. 4). The nucleotide sequence of all segments is 
known for several rotavirus strains. All are between 660 and 3300 bp in size and 
share the following general features (91):  
- lack of a poly(A) tail; 
- 5’ cap structure m7GpppG(m)GPy on the positive-sense strand; 
- uncapped minus-strand; 
- high content of A+U (58-67%); 
- complete complementarity of both RNA strands; 
- one single ORF (except for segment 11 of some strains). 
On one side the different genome segments share sequence signals in order to be 
transcribed and replicated by the same RdRp, on the other they contain signals to be 
distinguished from one another during packaging. While assembly and 
encapsidation signals remain still unknown, some of the signals for transcription and 
replication have been identified in both untranslated regions (UTRs) (76). In particular, 
for the medically important group A rotaviruses the plus-strand RNAs start with the 
consensus sequence 5’-GGC(A/U)6-8-3’ and end with the consensus sequence 5’-
UGUGACC-3’ (76) (Fig. 3). The conserved sequence at the 3’UTR has been 
identified as a signal promoting minus-strand RNA synthesis (215, 294). In particular, 
the 3’-terminal CC have been shown to be crucial for the formation of the initiation 





binding of the RdRp, which instead requires the four nucleotides 5’-UGUG-3’ of the 
3’-terminal consensus sequence and also other signals positioned in non-conserved 
regions positioned upstream (280). Within the same conserved sequence, the last 
four nucleotides 5’-GACC-3’ function as translation enhancers (56). The conserved 
sequence within the 5’-UTR, in particular the second G, has also been shown to play 
a role in the attachment of the RdRp and cofactors into a stable initiation complex for 
minus-strand RNA synthesis (281) (Fig. 3). Based on computer modelling, the 5’ and 
3’ UTRs are predicted to stably anneal to form a panhandle structure, from which the 
3’-terminal conserved sequence extends as un-base-paired tail (54, 206) and this 













Rotavirus genomes (better investigated for group A rotaviruses) show an extensive 
diversity, which is essentially due to the following mechanisms (135): 
FIG. 3:  Schematic representation of a group A rotavirus plus-strand RNA. The 
conserved sequences at the 5’ and 3‘ ends are indicated. Both sequences were 
shown to be essential for the formation of the minus-strand initiation complex. They 
are predicted to stably base-pair forming a panhandle structure. The dinucleotide 
GG indicated in purple is conserved within all groups of rotaviruses and the 
second G was shown to be essential for specific recognition by the polymerase 
VP1. Another recognition signal for VP1 is at the 3’UTR. Both signals are 





- accumulation, sometimes fixation, of point mutations (genomic drift); 
- genome segment reassortment (genomic shift): a dual infection with two co-
circulating human strains or a human and an animal strain leads to a viral 
progeny containing novel assortments of genome segments; 
- gene rearrangements (75): considerable tracts of sequence within a single 
genome segment may be altered by deletions or duplications. Most gene 
rearrangements involve segment 11 and consist in a partial head-to-tail 
duplication of the dsRNA sequence (113). 
 
2.4. GENE-PROTEIN ASSIGNMENT 
 
The genome segments code for six structural proteins found in virus particles 
(VP1, VP2, VP3, VP4, VP6, VP7) and five or six nonstructural proteins (NSPs) found in 
infected cells but not in mature virus particles (NSP1-NSP6; as mentioned above, 
some strains have only a single ORF in segment 11 and lack NSP6) (91). Some 
NSPs are found in subcellular locations, some others in cytoplasmic viral inclusion 
bodies called viroplasms and considered sites of viral genome replication and 
packaging (91).  
Comparative studies of the electrophoretic pattern of genome segments deriving from 
different strains have shown that the relative migration order of the eleven genes can 
differ (91). Therefore, the gene-protein assignment is specific for each strain (Fig. 4). 
Table 1 lists the RNA segments and their protein products for the simian rotavirus 
SA11 strain. All functions reported in literature for rotavirus proteins are also 
summarized. A more detailed description of their properties and functions is provided 
























ssRNA and dsRNA; NSP2; VP1; 
VP2; tubulin; NSP6
ssRNA and dsRNA; NSP5
Role in replication; viroplasm formation; 
ATPase activity











VP6; microtubules; laminin-β3; 
fibronectin; complex with VP4 
and VP7; α1β1 and α2β2 
integrins; caveolin-1 
Intracellular receptor for DLPs; role in 
linking packaging and morphogenesis, in 
morphogenesis and in regulation of 
transcription and calcium homeostasis; 
enterotoxin; viroplasm maturation
GlycosylationNonstructural20.3NSP475110
VP4; VP6; Ca2+; some integrins; 
complex with NSP4 and VP4; 






ssRNA; NTPs; NSP5; VP1; 
tubulin
NTPase/RTPase, NDP kinase, helicase 
activities; role in replication and possibly 














RNA; IRF-3; IRF-5; IRF-7Virulence (antagonizing innate immune 
response) 
Nonstructural58.7NSP116115
VP7; sialic acid or sialic acid 
derivatives; several integrins; 
Hsc70; TRAF2; Rab-5 and PRA-
1; complex with VP7 and NSP4
Cell attachment; protease-enhanced 







ssRNA; complex with VP1; VP2?Guanylyl-methyl transferaseInner core88VP325913
ssRNA and dsRNA; VP6; NSP5Required for replicase activity of VP1MyristylationCore94VP226902





FIG. 4:  PAGE gel showing the 11 
dsRNA genome segments of the 
rotavirus SA11 strain. The genome 
segments are numbered on the left 
and the encoded proteins are 
indicated on the right. Segment 11 
of this strain has also an alternative 
ORF encoding the nonstructural 
protein NSP6. 
TAB. 1:  Genes, gene protein assignments and published functions of proteins of group A 





3. ROTAVIRUS PROTEINS 
 
VP1 
VP1 is the viral RNA-dependent RNA polymerase (RdRp) acting as both, the 
transcriptase (for mRNA synthesis) and the replicase (for minus-strand RNA synthesis). 
Several lines of evidence indicate that VP1 is the viral RdRp: (i) VP1 contains 
sequence motifs that are shared by RdRps of other RNA viruses (188); (ii) VP1 has 
NTP-binding activity and, when cross-linked with the nucleotide analog 8-azido-ATP, 
inhibits RNA transcription (284); (iii) VP1 specifically recognizes multiple functionally 
distinct elements at the 3’ end of viral plus-strand RNAs (53, 207, 280); (iv) 
recombinant VP1 can direct template-dependent minus-strand synthesis in vitro in the 
presence of VP2 (212, 308). To date, regions of VP1 responsible for specific 
recognition of the templates and the enzymatic activity have not been identified and 
this is in part due to the lack of a solved 3D structure. Based on a bioinformatic 
programme comparing shared motifs of different viral RdRps, an overall structural 
conservation has been identified in the middle of the sequence, whereas the N- and 
C-termini have been predicted as unique regions (288), which could be related to 
unique functions of VP1 or to interactions with specific rotavirus proteins. Interactions 
of VP1 with NSP2 (145) and NSP5 (2, 8) have been described by 
coimmunoprecipitation experiments from extracts of both infected and transfected 
cells. Moreover, VP1 may interact with VP2 because: (i) they form virus-like particles 
(VLPs) when coexpressed in insect cells (307, 308); (ii) purified recombinant VP1 and 
VP2 can drive synthesis of dsRNA in template-dependent assays only when both are 
present (212, 280); (iii) far-Western blot analysis showed a binding between VP1 






VP2 is the major scaffolding component of rotavirus core: 120 molecules of VP2 form 
the innermost capsid layer of rotavirus enclosing the genomic dsRNA (153). Since 
VP2 is the only protein capable to form stable VLPs when expressed alone in insect 
cells or also in various combinations with VP6, VP4 and VP7, it has been considered 
the rotavirus scaffolding protein (62, 153). However, VP2 shell has both a structural 
and a functional role: interactions with trimers of VP6 (forming the intermediate 
particle layer) are responsible both for the stability of DLPs and for mRNA synthesis 
and transcript extrusion (48, 162); VP2 binds to genomic dsRNA, as demonstrated 
by UV cross-linking experiments (152), and its higher affinity for ssRNA than for ds 
nucleic acids (35) suggests a possible role in the encapsidation of ssRNAs used as 
templates for dsRNA synthesis; in fact, VP2 is required by VP1 in in vitro replication 
assays to achieve the replicase activity directing minus-strand synthesis (212, 280). 
The N-terminus of VP2 is responsible for both its nonspecific RNA binding activity 
(35, 152) and the proper assembly of VP1 and VP3 into the core (307) forming a 
complex located on the inner surface of the VP2 layer at the icosahedral fivefold axes 
(234). More in detail, deletion of the first 26 amino acids completely abolished the 
RNA binding activity, indicating that either the first 26 amino acids contain the 
binding site(s) or they allow VP2 to fold in such a way that RNA binding can occur 
through several other RNA binding sequences identified in the first 132 amino acids 
(152). Baculovirus recombinant-mediated co-expression of N-terminally truncated 
forms of VP2 and VP1 and/or VP3 showed that the N-terminal 92 aminoacids are 
essential for incorporation of VP1 and VP3 in virus-like particles (VLPs), although they 
are not for VP2-VLP formation (307). Moreover, far-Western blot analyses using a 





terminal truncation lacking amino acids 1 to 25 fails to bind VP1 and a C-terminal 
296-aa truncation maintains the ability to bind VP1 (307).  
By cryoelectron microscopy and image reconstruction of VLPs formed either by full-
length VP2 or by the truncation lacking the N-terminal 92 amino acids, it has been 
proposed that the 120 molecules of VP2 are arranged as dimers, each extending 
between neighbouring fivefold axes, and that the N-termini are located near the 
icosahedral vertices (159). Interestingly, previous cryoelectron microscopy 
experiments on native DLPs had shown significant interactions between the inner 
surface of VP2 layer and the genomic dsRNA near the icosahedral fivefold axes and 
minor interactions along the icosahedral twofold axes (234), supporting the idea of 
VP2 having an important role in organizing the genomic dsRNA within the core. 
While the N-terminal region of VP2 seems to be essential for the spatial architecture 
of the core, it does not seem to be involved in interactions with VP6 and with the 
nonstructural protein NSP5. It has been reported that both full-length VP2 and a VP2 
deletion mutant lacking the N-terminal 92 amino acids can form VLPs incorporating 
VP6 (49) and both coimmunoprecipitate with NSP5 and form aggregate structures in 
insect cells with NSP5 and VP6, and with either of them (23). Moreover, it has been 
shown that an insect cell lysate containing recombinant baculovirus-derived NSP5 
dislodges VP6 from purified VLPs formed by VP2 and VP6, but not from purified DLPs 
(23). Since the differences between the two types of purified particles are the 
presence of genome segments and the stronger interaction between VP2 and VP6 in 
DLPs, it has been proposed that the interaction between the VP2 core and NSP5 
occurs at early times to prevent the VP6 binding and thus the formation of defective 






VP3 is a basic protein responsible for capping rotavirus mRNAs through its guanylyl-
transferase and methyl-transferase activities (52, 164, 225). It is one of the minor 
components of the core (163), a component of early replication intermediates and, 
together with VP1, seems to be the first protein to associate with viral (+)ssRNAs 
during packaging and RNA replication (104), possibly through its unspecific affinity 
for ssRNA (209). Together with VP1 and ssRNA, VP3 interacts with the N-terminus of 
VP2 (307) and this association might have a role in RNA replication. In fact, it has 
been shown that the presence of a functional VP3 is important for RNA replication 
(286) and that in in vitro replication assays VLPs containing VP1, VP2 and VP3 
synthesize minus-strand RNAs more efficiently than VLPs formed only by VP1 and VP2 
(308). The exact role of VP3 in this context is unclear. It has been proposed that VP3 
increases the rate at which the components of the replicase complex assemble into 
functional structures (212). 
VP4 
VP4 is one of the two proteins of the outer layer of rotavirus. It is a non-glycosylated 
protein with essential roles in virus attachment and penetration. Antibodies against 
VP4 can neutralize by blocking cell entry and protect against rotavirus gastroenteritis 
(201, 244). In virions uncleaved with trypsin, molecules of VP4 are distributed on the 
surface of the VP7 shell as flexible stalks occupying each of the 60 symmetry-
equivalent positions. In the gut lumen trypsin cleavage of VP4 maximises rotavirus 
infectivity (94, 98): this cleavage generates two fragments, VP5* (60KDa) and VP8* 
(28KDa), which remain associated with virions and confer the spike appearance of 
VP4 observed by cryoelectron microscopy in trypsin-cleaved virions (260, 299). 
VP8* forms the “heads” of the spikes and binds cellular receptors in the virus 





“body”, which is linked by an asymmetric “stalk” to a “foot” buried beneath the VP7 
shell (81) and interacting with VP6 (299). The VP5* residues in the spike body are 
involved in membrane penetration and integrin binding (83, 120, 171). It appears 
that each spike is indeed a VP4 trimer (81) and that the rearrangement induced by 
trypsin cleavage allows a switch from a flexible structure into rigid spikes (64, 81), 
where two primed VP4 molecules are associated and present the VP8* core for 
receptor binding and the third primed VP4 molecule is flopping and not visible by 
cryo-EM (81) (Fig. 5A). It has been proposed that a second rearrangement event 
occurs during cell entry, in which two VP5* subunits fold back on themselves and join 
a third VP5* subunit to form a tightly associated trimer, shaped like a folded 
umbrella, from which VP8* dissociates (81) (Fig. 5B). This second rearrangement is 
thought to occur to unmask the membrane interaction region of VP5* allowing cell 
penetration (81). To support this VP4 rearrangement model, there is the evidence that 
a globular domain of VP5* containing the potential membrane interaction region has 
the intrinsic molecular property of alternatively forming dimers and trimers (301). As a 
further confirmation, it has been observed that at elevated pH the VP4 spike 
undergoes an irreversible conformational change from a bilobed structure to a 











VP8* contains a sialoside-binding region within a shallow groove on its surface, 
which is involved in sialic acid binding and hemagglutination in sialidase-sensitive 
rotavirus strains (82, 98). However, the capacity of VP8* of binding sialic acid 
derivatives has also been recognized for some sialidase-insensitive strains (28), and 
new carbohydrate binding regions in VP8* are being discovered in both types of 
strains (28, 82, 127). Interestingly, the VP8* sialic acid binding domain has a 
galectin fold, which might be responsible for features shared by VP4 and galectins, 
like the translocation to the plasma membrane via a Golgi-independent pathway or 
the capacity of activating the TRAF2-NF-kB-inducing kinase signalling pathway (155). 
The binding of VP8* to TRAF2, a member of a family of adapter proteins involved in 
transducing signals generated by ligands of Tumor Necrosis factor (TNF), and the 
consequent activation of NF-kB, which in turn causes the secretion of selected 
chemokines, suggests a role for VP4 in determining cell-specific responses to rotavirus 
infection (155). 
FIG. 5:  Models of two VP4 conformations. (A) The primed state. Two rigid subunits form 
the spike visible in electron cryomicroscopy image reconstructions of trypsin-primed virions. 
A third subunit is flexible. VP8* is represented in gray, VP5* in green bean-shape, with a 
red membrane interaction region. (B) The putative post-membrane penetration state. VP8* 





VP5* is involved in cell attachment (304, 305) and is considered the main part of 
the molecule responsible for cell entry through a hydrophobic fusion domain that was 
shown to be able to permeabilize membranes in the absence of other rotavirus 
proteins (72). Since it was found that VP5* cannot permeabilize lyposomes or 
bacteria, it has been proposed that it has a selective permeabilizing activity, possibly 
by forming transient pores that could allow the decrease of calcium levels in the 
proximity of the plasma membrane or in endosomes (83, 107). VP5*, together with 
VP7, is also responsible for integrin binding, which is important not only for cell 
attachment and entry (involving mainly α2 integrins), but also for facilitating virus 
spread or host immune response modulation (involving mainly α4 integrins) (119, 
129, 304): through its peptide sequence DGE, VP5* interacts with α2β1 integrin 
(120, 121, 128) and it is likely to be involved in binding to α4β1 and α4β7 
integrins through its peptide sequence YGL (119). Furthermore, VP5* has been 
shown to bind Hsc70 (303) in a post-attachment step important for cell entry (124). 
The role of VP4 in the morphogenesis of rotavirus has been studied by experiments of 
RNA interference silencing VP4 expression (65, 67). The formation of spike-less TLPs 
in rotavirus-infected cells transfected with an siRNA against VP4 suggested that VP4 is 
not required for virus assembly (67). Since these spike-less TLPs have larger diameter 
than wild-type TLPs, it has been proposed that VP4 tightens the structure of the viral 
particle (67). Interestingly, VP4 silencing reduces the association of rotavirus particles 
with rafts and causes an accumulation of non-enveloped particles in the endoplasmic 
reticulum (ER) (65), suggesting a role for VP4 in trafficking newly synthesized 
particles. Many reports indicate that VP4 is indeed associated with rafts (68, 252), 
which are dynamic microdomains in cellular membranes enriched in cholesterol and 
sphingolipids and exert critical roles in membrane trafficking. However, the role of 





newly synthesized VP4 seems to be localized both in the cytosol and in the plasma 
membrane, starting early after infection. More precisely, it has been detected in an 
area between viroplasms and ER (220), colocalizing in the ER proximity with NSP4 
(108), with which it might interact (10), also because of the recognized ability to 
form heterotrimers with NSP4 and VP7 (170). It has also been identified in the ER-
Golgi Intermediate Compartment (ERGIC) (65), in transiently enveloped particles 
(229) and in the plasma membrane in lipid rafts, associated with microtubules and 
exposed on the external face of the apical plasma membrane (69, 196, 252). The 
data from RNA interference experiments, the VP4 cellular distribution, the described 
interactions [with NSP4/VP7 and with the ER chaperone grp78 (296)], and the fact 
that VP4 needs to be added before VP7 to reconstitute in vitro infectious TLPs from 
non-infectious DLPs (283), support the idea that VP4 assembly into particles occurs 
inside or in the vicinity of the ER and not at a later time point when VP7-coated 
particles are already formed. However, since rafts are considered to be absent in the 
ER and the block of enveloped particles in the ER induced with chemical reagents 
does not correlate with a reduced cell surface targeting of VP4, it has been proposed 
that VP4 assembly in viral particles occurs as a post-ER event (69). Thus, two pools of 
VP4 might exist, one associating with viral particles in the ER and the other 
independently targeted to the plasma membrane (65). Further experiments are 
needed to prove this assumption. Finally, an involvement in localization and 
trafficking of the free cytosolic VP4 in infected cells has been suggested for two 
cellular proteins, Rab-5 and PRA1, both participating in vesicular trafficking and able 
to form complexes with free VP4 at late steps of infection (88). 
VP6 
VP6 is the major capsid protein of rotavirus. It forms 260 trimers that constitute the 





elongated, tower-like molecule, where the three subunits wrap around a central 3-fold 
axis with a right-handed twist. The VP6 monomer consists of two domains (H and B) 
positioned along the long dimension of the tower-like molecule and both involved in 
intra-trimer interactions. Each trimer contains conserved surfaces for interactions with 
other structural proteins, at the bottom for binding to VP2, at the top for contacting 
VP7, at the sides of domain H for binding to VP4 and at the sides of domain B for 
lateral interactions with other VP6 trimers. These inter-trimer interactions do not contain 
all the information to form a closed icosahedral shell, since interactions with the VP2 
inner layer are also required for a correct assembly. A model for assembly has been 
proposed, in which the center of each of the twenty faces of the VP2 layer acts as a 
nucleation point for the growth of the middle layer and the driving force for assembly 
propagation appears to be the inter-trimer interactions rather than interactions with the 
VP2 layer (1, 174). A Zn2+ ion is located at the center of the VP6 trimer coordinated 
by three histidines, one for each VP6 monomer (174). Mutation of the Zn2+ 
coordination site renders the trimer more sensitive to proteases, but has no effect on 
the interaction with VP2 or on the DLP transcription activity (89). When coexpressed 
in insect or mammalian cells, VP2 and VP6 can in fact form double-layered virus-like 
particles (Dl-VLPs) (62, 110). However, while recombinant VP2 is able to form core-
like particles in insect cells by itself (153), VP6 forms only tubular or spherical 
structures in the absence of other viral proteins (161, 240). The spherical structures 
are larger than Dl-VLPs, highlighting the importance of VP2 in the assembly of viral 
particles (161). The main parameter affecting interactions between VP6 molecules, 
and consequently the formation of spheres or tubes, is pH: at pH 3.5-5.5 these 
interactions generate spherical particles, at pH 5.5-7.0 large tubes and at pH above 
7.0 small tubes (161). These observations suggested that the protonation state of VP6 





By connecting the outer layer and the inner layer, VP6 has a fundamental role in the 
structure of the virion as a physical adapter between the biological functions exerted 
by the two linked layers: cell entry and genome packaging (233). Moreover, VP6 
seems to play an active role in transcription, because in its absence the process does 
not take place (24). In particular, it has been shown that: (i) hydrophobic interactions 
at the interface with VP2 are responsible for the DLP stability and subtle electrostatic 
interactions in the same area influence transcription and transcript extrusion (48); (ii) 
structural changes induced by anti-VP6 antibodies (97, 156) or the geometrical 
orientation of the trimers induced by interaction with VP7 (162) inhibit transcriptional 
activity. VP6 might also have a role in the budding of newly formed DLPs in the ER: in 
fact, during viral infection VP6 is localized at the periphery of viroplasms and in close 
proximity of the ER (220) and is thought to interact with the cytoplasmic tail of NSP4 
(180, 275, 277), which is the viral ER-transmembrane protein mediating the budding 
of viral particles into the ER (9, 10, 19). Interestingly, NSP4 silencing experiments 
showed a drastic change of the VP6 distribution in infected cells: instead of being 
localized in viroplasms, in the absence of NSP4 VP6 forms filaments not colocalizing 
with tubulin, actin or vimentin (165). Furthermore, the same phenotype was observed 
when the expression of another nonstructural protein was silenced: NSP5 (166). 
However, at present there is no evidence of an interaction between VP6 and NSP5. 
On the contrary, it has been shown that NSP5 does not bind DLPs and that VP6 
hinders the interaction between NSP5 and VP2 (23). 
VP7 
VP7 is a protein organized in 260 trimers forming the outer layer of rotavirus (300), 
in which VP4 molecules are inserted. In most rotavirus strains, but not in all of them, 
VP7 is N-glycosylated. It has a high content of conserved cysteines that form disulfide 





particles (185). During the replicative cycle the newly synthesised VP7 is inserted in 
the ER membrane with a luminal orientation (143). The VP7 targeting to the ER is due 
to two hydrophobic regions located at the N-terminus, which are cleaved off after 
insertion of VP7 in the ER membrane, but are still necessary for the retention of VP7 in 
the ER (169, 231, 266, 295). The C-terminus is thought to be protruding into the 
cytoplasm and have important roles for the assembly of mature particles (60).  
The conformation and stability of VP7 are calcium-dependent (79); in particular, the 
trimerization of VP7 requires calcium (80). In fact, many lines of evidence indicate 
that both the loss of the outer layer during cell entry and the formation of the same 
layer during virus assembly are mediated by calcium-dependent conformational 
changes of VP7: in vitro calcium chelation triggers TLPs uncoating (61); the outer 
layer contains calcium (258); low concentrations of calcium induce a VP7 
solubilization (103, 247) shown to be necessary for the permeabilizing activity of the 
protein (47); in the absence of calcium, VP7 cannot interact with VP4 and NSP4 in 
the heterotrimeric complex formed during virus assembly (170, 230). 
VP7 has an important role during cell entry, not only because of its membrane 
permeabilizing activity (47), but also because of its binding to αvβ3 (306) and αxβ2 
integrins (120). VP7 also has a regulatory role in transcription, because it appears to 
induce a structural change of VP6 (156) and a reorganization of the VP6 trimer 
around the particle 5-fold axes (162) that inhibit the DLP transcriptional activity; 
moreover, it causes a steric hindrance that blocks the exit of nascent mRNAs through 
the type I channels (159). VP7 silencing experiments also revealed an important role 
of VP7 in removing the transient envelope during virus morphogenesis (165) and a 







NSP1 is an RNA-binding nonstructural protein that accumulates in the cytoplasm of 
infected cells in association with the cytoskeleton (132). It is the least conserved 
rotavirus protein; only the N-terminal zinc binding motif is completely conserved 
(189). This cystein-rich region has been shown to be essential for binding viral RNAs 
at the 5’UTR (37, 131) and it is important, but not sufficient, for allowing NSP1 
binding to the cellular transcription factor IRF3 (Interferon Regulatory Factor 3) (117). 
This cellular protein is activated following virus infection and promotes the expression 
of IFNβ, which is secreted and induces the neighbouring uninfected cells to express 
another transcription factor, IRF7 (253). IRF7 is the main molecule responsible for the 
production of type I IFN (IFNα and β) in the anti-viral host response. NSP1 has been 
shown to target IRF3 to the proteasome (14), and it has been proposed to act as a 
E3 ubiquitin protein ligase based on the fact that the arrangement of the cysteine 
residues of the zinc binding motif resembles the RING fingers of the E3 ligase (116). 
However, NSP1 of some rotavirus strains does not have IRF3 as a target, despite 
having an intact zinc-binding domain (116). Furthermore, it has recently been shown 
that NSP1 induces the proteasome degradation of IRF7 (15). This is probably related 
with the ability of the virus to replicate in specialized trafficking cells (macrophages 
and dendritic cells) constitutively expressing IRF7 (11) and IRF5, which is another 
factor that upregulates IFNI expression and is involved in triggering apoptosis during 
viral infection (15). Therefore, NSP1 may be considered as a broad-spectrum 
antagonist of the innate immune response that limits the virus spread (15). Since 
truncated forms of NSP1 lacking portions at the C-terminus lose their ability of 
interacting with these IRF factors, the C-terminus seems to play an important role in this 
context and its sequence variability in strains infecting different animal species 





has thus an important role in virus spread, confirmed also by reassortment experiments 
that showed a strong correlation between the genome segment encoding NSP1 and 
virus virulence and spread (36) and by the demonstration that truncations of NSP1 
are responsible for the formation of smaller plaques following rotavirus infection 
(214). However, NSP1 does not have a role in virus replication, since virus mutants 
encoding C-truncated forms of NSP1 replicate efficiently (214) and NSP1 silencing 
by RNA interference does not affect virus replication (261). 
Interestingly, it has been shown that the stability of NSP1 is maintained by the other 
viral proteins, alone or in combination with viral RNA, since in their absence the 
proteasome-mediated degradation of NSP1 is significantly increased (222). 
NSP2 
NSP2 is a basic, conserved protein with an important role in virus replication. This 
role has been demonstrated both by analysis of cells infected with a temperature-
sensitive (ts) mutant of SA11 rotavirus strain, tsE(1400), with a lesion in the genome 
segment encoding NSP2 (239) and by RNA interference experiments in which NSP2 
expression was silenced (261). Both the growth of cells infected with tsE(1400) at a 
non-permissive temperature and the NSP2 silencing revealed a critical function of 
NSP2 in viroplasm formation, in genome replication and packaging and in the 
production of infectious viral progeny (239, 261). The requirement of NSP2 in 
viroplasm formation is also confirmed by the fact that NSP2 forms viroplasm-like 
structures (VLS) when transiently coexpressed with NSP5 in the absence of other viral 
proteins (96) (see Fig. 9 in chapter 4). Moreover, NSP2 has been found in early 
replication complexes (104, 211) and the immunoprecipitation with a monoclonal 
antibody against NSP2 of an extract of infected cells allowed to recover a viral 





The functional form of NSP2 is a doughnut-shaped octamer derived from self-
assembly of NSP2 monomers and from tail-to-tail interactions of two tetramers (138, 








Each monomer has two distinct domains separated by an electropositive deep cleft 
that contains a histidine triad (HIT)-like motif (138) responsible for binding and 
hydrolysis of NTPs (46). The catalytic residue of this motif is a His in position 225, 
which becomes phosphorylated through the covalent attachment of the γP released 
after a Mg2+-dependent hydrolysis reaction of the linkage between the γ and β 
phosphates (46, 151, 287). To catalyze this reaction, NSP2 can use both NTPs 
(270) and pppRNA (287) as substrates, thus exerting both NTPase and RTPase 
activities. Moreover, the NTPase activity has been shown to be associated with a 
phosphoryl-transfer function to NDPs similar to that of cellular NDP kinases (151). 
While the enzymatic activities of NSP2 can be attributed to the monomeric subunits, 
FIG. 6:  NSP2 Structure. Structure of the NSP2 monomer (left), showing a deep cleft (arrow), which 
may be the site for NTP binding. Structure of the functional NSP2 octamer showing a view down the 
four-fold (middle) and a view down one of the two-fold axis in octamer (right). The deep grooves 
shown (right, arrows) are lined by basic residues and may be the sites for binding viral mRNA during 





its binding properties require the formation of the octamer. More in detail, it has been 
shown that NSP2 has a sequence-independent ssRNA binding (270) and a nucleic 
acid helix destabilizing activities (272) and it is able to bind NSP5 (2, 85, 139) and 
VP1 (8, 145); the 35Å central hole of the octamer, lined by neutral residues, was 
shown to be not involved in RNA and NSP5 binding, for which instead the four deep 
positively-charged grooves extending diagonally across the octamer are required 
(139). Interestingly, the binding sites of NSP2 with RNA and with a NSP5 mutant 
lacking the first 65 amino acids and the last 10 amino acids correspond, suggesting 
a competition between NSP5 and RNA for interaction with NSP2 (139). 
Furthermore, coimmunoprecipitation of NSP2 with NSP5 using anti-NSP5 antibodies 
was shown to require UV treatment, and to occur even after RNase digestion of the 
cellular extracts (2). Based on these findings, it has been suggested that NSP2-NSP5 
interaction is not directly mediated by RNA and may be the consequence of a 
conformational change in NSP2 bound to RNA and/or nucleotides stabilised by the 
UV treatment (2). 
The ssRNA binding and helix-destabilizing activities of NSP2 have been suggested to 
relax positive-strand RNA templates to facilitate genome replication (272) and the 
NSP5 binding seems to be important for viroplasm formation (96) and might regulate 
the NSP2-RNA interaction during genome replication (139). On the other hand, the 
roles of the enzymatic activities remain completely obscure. In vivo complementation 
studies have shown that the HIT-dependent enzymatic activities are necessary for 
dsRNA synthesis, but not for viroplasm formation, and it has been hypothesized that 
these activities are used only after establishment of cellular sites of replication and 
assembly (271). This could have something to do with the fact that the NTP binding 
causes a conformational change from a more relaxed to a more compact form of 





whilst NSP5 binding does not (139). Moreover, it has been shown that a ssRNA 
molecule with a 5’ γ-phosphate is preferred to NTPs as a substrate (287), suggesting 
that the hydrolytic activity of NSP2 may regulate the ssRNA binding activity or vice 
versa. Interestingly, the NSP5 binding activity does not interfere with the enzymatic 
activity of the HIT-like motif (287) and the catalytically inactive NSP2 mutant H225A 
supports VLS formation (46). Since NSP2 was found in early replication complexes, it 
has been proposed that the RTPase activity removes the γ-P from nascent negative-
strand RNAs, but not from positive-strand RNAs because of the capping modification 
interfering with the RTPase function (287). However, dsRNAs are not substrates for 
the RTPase activity of NSP2 either and the role of this activity remains still obscure. 
For the NDP kinase activity, a role in the homeostasis of nucleotide pools has been 
suggested: NSP2 would guarantee sufficient levels of NTPs for transcription and 
replication and of ATP for processes requiring energy like transcription, NSP5 
phosphorylation, RNA packaging and translocation (151), and the recently reported 
ATP-ase activity of NSP5 (13). Besides NDPs, also NSP5 had been proposed as a 
substrate for the phosphotransfer activity of NSP2 (290), however it has then been 
shown that the catalytic activity of NSP2 is not involved in the phosphorylation of 
NSP5, since NSP2 mutants that are NTP-ase defective still promote NSP5 
hyperphosphorylation (46). Interestingly, and surprisingly, in vitro replication assays 
with recombinant VP1 and VP2 showed that NSP2 inhibits the initiation phase, but 
not the elongation phase, of the synthesis of dsRNA through its nonspecific RNA 
binding activity (291). More precisely, NSP2 does not block the recognition of the 
template by the polymerase, instead it interferes with the function of VP2 through an 






NSP3 is a slightly acidic protein, whose role in the viral replicative cycle is still not 
completely clarified. During virus infection, NSP3 is distributed diffusely throughout the 
cytoplasm, possibly associated with the cytoskeleton (177). NSP3 is composed of 
two functional domains separated by a dimerization domain (223). The N-terminal 
domain is required for sequence-specific RNA binding and the dimerization is 
necessary for the strong binding of a single molecule of RNA (74, 223). The 
sequence GACC within the consensus sequence at the 3’UTR of all viral mRNAs has 
been demonstrated as the shortest target recognized by NSP3 (227), and the 
binding of NSP3 to this sequence protects the 3’ end from RNase digestion (226). 
Interestingly, NSP3 can recognize only mRNAs derived from the same serogroup, 
which could be one of the reasons why genomes of rotaviruses of different 
serogroups cannot reassort (227). The central domain of NSP3 is responsible for 
dimerization, forming a coil-coiled structure that confers to NSP3 dimer a heart shape 
(74, 223). By yeast two-hybrid assays, this domain has also been shown to be 
involved in interaction with RoXaN (Rotavirus X protein associated with NSP3), which 
is represented by two related proteins in mammalian cells (RoXaNI and RoXaNII) that 
might be important for translation regulation (292). In fact, RoXaNI can form a ternary 
complex with NSP3 and the other cellular ligand of NSP3: eIF4GI (eukaryotic 
Initiation Factor 4GI) (292). The NSP3 C-terminal domain is indeed involved in 
interaction with this cellular factor (223, 224), which is a scaffolding protein that 
binds the cap binding protein eIF4E, the RNA helicase eIF4A and the poly(A)-binding 
protein (PABP), in order to promote an efficient initiation of translation (134, 237, 
274). NSP3 binds to eIF4GI in the same region recognized by PABP (224): it has 
been proposed that by bridging the cap-binding protein eIF4E via its binding to 





sequence, NSP3 promotes the circularization of viral mRNAs and their translation, 
while evicting PABP from eIF4GI impairs the translation of cellular mRNAs (224, 
289). While there is a general agreement on the inhibitory activity of NSP3 on the 
synthesis of cellular proteins (191, 202, 224, 289), supported also by the recent 
observation that NSP3 causes a translocation of PABP to the nucleus (192), the role 
of promoting synthesis of viral proteins is now brought into question: in fact, RNA 
interference experiments that silenced NSP3 expression showed that NSP3 is not 
required for viral protein synthesis and, even more, its silencing correlates with an 
increased synthesis of viral RNA and with a concomitant increase in the yield of viral 
progeny (191). Furthermore, silencing the eIF4GI expression confirmed that its 
interaction with NSP3 is not required for viral protein synthesis (191). It has then been 
proposed that the interactions with eIF4GI and with the 3’ end of viral RNAs have 
two distinct functions: the first would help sequestering eukaryotic translation initiation 
complexes, thus inhibiting cellular protein synthesis, the second would prevent viral 
plus-strand RNAs from being selected for replication, thus ensuring a pool of 
transcripts available for translation, or would protect viral mRNAs from degradation 
(191). 
NSP4 
NSP4 is a multifunctional nonstructural glycoprotein (143) with key roles in virus 
transcription, morphogenesis and pathogenesis. It is the only nonstructural protein that 
does not bind to RNA. It is a 175 amino acid long, transmembrane protein targeted 
to the ER membrane by a signal sequence, which remains uncleaved. After insertion 
in the ER, most of the protein is exposed in the cytosol. NSP4 contains three 
predicted hydrophobic domains, H1, H2 and H3. H1 is a small domain, which is 
N-glycosylated in two sites and located in the ER lumen; H2 is a transmembrane 





region in the cytosolic C-terminus downstream the H3 domain was shown to be 
involved in the ER retention (183); H3 is embedded in lipid bilayers on the 
cytoplasmic side of the ER (19) and is followed by a predicted amphipathic α-helix 
(AAH), which overlaps a folded coiled-coil region and is thought to mediate NSP4 
oligomerization into dimers and tetramers stabilized by Ca2+ (32, 170, 277); finally, 
a hydrophilic C-terminus forms an extended cytosolic domain involved in binding of 
immature viral particles (DLPs) (31, 32, 143, 200, 277). Adjacent to the AAH 
region there is a microtubule-binding domain (297). Corresponding to the coiled-coil 
oligomerization domain there is also a region that binds two proteins of the 
extracellular matrix, laminin-β3 and fibronectin, with implications for the role of NSP4 
in pathogenesis (30). In addition, the final part of the same domain contains two 
distinct integrin interaction motifs, shown to be responsible for binding to α1β1 and 
α2β1 integrins and for triggering signalling cascades important for the enterotoxin 
function of NSP4 (257). Furthermore, the same region is involved in a hydrophobic 
interaction with caveolin-1, a component of a subset of lipid raft microdomains called 
caveolae, which is thought to be involved in the intracellular transport of NSP4 (182, 
204, 267). As already mentioned, the C-terminus of NSP4 acts as an intracellular 
receptor that binds newly made DLPs and mediates their budding into the ER lumen 
(9). More in detail, it has been shown that the extreme twenty residues of the C-
terminus bind to VP6 (200), and that a region comprising part of the coiled-coil 
domain and part of the C-terminus contains sites important for VP4 binding (10). 
Upon budding of DLPs into the ER, NSP4 has been shown to hetero-oligomerize with 
VP4 and VP7 (170). The C-terminus of NSP4 has also enterotoxigenic properties: in 
fact, the region spanning amino acids 112–175 can be cleaved through a still 
unknown mechanism and secreted from rotavirus-infected cells to function as an 





The two N-linked high-mannose oligosaccharide residues of NSP4 appear to be 
critical for the assembly function of NSP4, as treatment of infected cells with 
tunicamycin, a drug that blocks N-linked glycosylation, leads to the accumulation of 
enveloped particles in the ER (69, 218). The fact that the only other glycoprotein of 
rotavirus, VP7, is unglycosylated in some strains suggests that the oligosaccharides of 
NSP4 are those important for virus assembly. With this regard, glycosylation of NSP4 
was reported to be not essential for NSP4 binding to DLPs or for oligomerization, but 
required for binding with the ER-associated molecular chaperon calnexin in an 
interaction shown to be not critical for virus assembly (184). The exact role of NSP4 
glycosylation remains still unclear. 
Three pools of NSP4 with different functions have been identified in infected cells: 
- a first pool is represented by the NSP4 molecules localized in the ER 
membrane with the role of mediating the budding of immature viral particles 
into the ER, as described in paragraph 4.6 (91); 
- a second pool comprises the NSP4 molecules localized in the ERGIC 
compartment and in the plasma membrane through their association to 
microtubules, lipid rafts or caveolae: these molecules might have a role in 
directing trafficking of vesicles carrying newly formed viral particles to the 
plasma membrane, as described in paragraph 4.7, or be simply detected 
there during their transit as “free NSP4 molecules” towards the plasma 
membrane and the extracellular environment. With this regard, there are 
reports in favor of a Golgi-independent pathway for trafficking NSP4 through 
the cell (142, 204, 267, 297, 309) and there is also a report showing that 
full-length NSP4 can be actively secreted through a Golgi-dependent pathway 
(40). This discrepancy has been attributed to the fact that the NSP4 molecules 





secreted through the Golgi-dependent pathway are involved in the enterotoxin 
function (40); 
- the third pool includes NSP4 molecules distributed in cytoplasmic vesicular 
structures associated with the autophagosomal marker LC3 and with 
viroplasms; they have been proposed to promote the formation of large 
viroplasms by recruiting early viroplasms into putative “scaffold vesicles” (21). 
Silencing NSP4 expression with siRNAs revealed the involvement of NSP4 in many 
aspects of the replicative cycle: regulation of calcium homeostasis (302), 
translocation of viroplasmic proteins (165, 262), viroplasm maturation (262), 
assembly of packaged particles (165, 262), association of rotavirus particles with 
rafts (65) and, finally, regulation of viral transcription by limiting plus-strand RNA 
accumulation (262). This latter function is thought to be exerted by NSP4 promoting 
conversion of transcriptionally active DLPs into quiescent TLPs (262).  
NSP4 has also been identified as an enterotoxin (12, 137, 309). In fact, the 
delivery of purified recombinant NSP4 or synthetic NSP4 peptides into animal 
models causes age-dependent diarrhoea (12, 130). NSP4 is thought to exert its 
enterotoxigenic activity both after secretion as a truncated peptide (309) or as a full-
length protein (40) and directly as soon as it is synthesized in infected cells (20, 38, 
269). In both cases, an increase in calcium levels is observed, which has also been 
correlated with an age-dependent Cl- secretion (193). However, in the first case, this 
calcium increase is mediated by the activation of signalling pathways involving 
phospholipase C (PLC) (78) or phosphoinositide-3-kinase (PI3K) (257) after interaction 
with receptors located in neighbouring cells. Among these, α1β1 and α2β1 integrins 
have recently been identified (257). In the second case, NSP4 modifies the plasma 
membrane permeability (197), increaseas the intracellular calcium levels through a 





calcium-dependent manner by altering the phospohrylation status of the remodelling 
protein cofilin (20). Changes in subcortical actin dynamics can affect cellular 
processes like endo- and exocytosis, tight-junction biogenesis and ion transport, thus 
directly contributing to rotavirus pathogenesis (20, 39, 141, 199, 269). 
NSP5 
NSP5 is a highly conserved O-glycosylated phosphorylated nonstructural protein 
(112, 293) with affinity for ssRNA and dsRNA (290) and capable of forming 
homomultimers (109, 228). It plays a key role in the rotavirus replication cycle, as 
demonstrated by its silencing through siRNAs (45, 166). In fact, the lack of NSP5 in 
infected cells results in the significant reduction of viral proteins, viroplasms, viral 
transcripts, dsRNA genomes, and viral progeny (45, 166). Also the distribution of the 
viral proteins is affected, most of them appearing dispersed instead of concentrated 
in viroplasms, with the peculiarity of VP6 shifting from a viroplasm location to a 
fibrous array (166). The involvement of NSP5 in rotavirus replication is also 
suggested by its detection in early replication complexes (104), by its interaction with 
the two structural proteins essentially involved in genome replication, VP1 and VP2 
(2, 8, 23), by its localization in viroplasms (220) and by the fact that it forms VLS 
when coexpressed with NSP2 in uninfected cells (96) (see Fig. 9 in chapter 4). 
However, the exact roles in rotavirus replication of NSP5, of its post-translational 
modifications and also of its interactions remain still unclear. NSP5 has been 
extensively studied both in the full-length format and in many truncated variants, which 
provided insight into the involvement of different NSP5 regions in processes like 
viroplasm formation, phosphorylation, capability of multimerizing and interactions 
with other viral proteins. 
The NSP5 polypeptide consists of 196-198 amino acids (depending on the virus 





SDS-PAGE, displays several phosphorylated isoforms, of which the most abundant is 
the band at 28KDa, followed by the band at 26KDa; there is then a heterogeneous 
pattern of fainter bands of molecular weight ranging from 32 to 34KDa (3, 26, 
228). All these bands were shown to correspond to phophorylated isoforms by 
labelling experiments (3, 26, 228), even the band at 26KDa that is resistant to 




As already mentioned, NSP5 is post-translationally modified by O-linked monomeric 
residues of N-acetylglucosamine (3, 112). Since lambda-phosphatase (λ-PPase) 
treatment of NSP5 labelled with [1,6-3H]glucosamine showed that all bands can be 
converted into the 26KDa form with no loss of carbohydrate moieties, the addition of 
phosphates rather than O-glycosylation has been suggested to generate the different 
mobilities of the 26, 28 and 32-34KDa forms (3). 
While the role of O-glycosylation is completely unknown, a lot of data, sometimes 
controversial, have been collected on multimerization and phosphorylation processes. 
NSP5 forms homomultimers through a region mapped to the 20 C-terminal amino 
acids, which have a predicted α-helical structure (256, 279). Consistent with this, 
mutants lacking the 10 C-terminal or the 18 C-terminal amino acids are unable to 
FIG. 7: SDS-PAGE analysis of NSP5. Lane 1: 
immunoblot analysis of extracts of SA11-infected 
MA104 cells (4h post-infection) reacted with anti-
NSP5 serum. Lanes: 2-4: immunoprecipitation of 
NSP5 from virus-infected cells labelled in vivo with 
[35S]-methionine and treated with phosphatases, as 





multimerize (228, 279); in addition, the conserved cysteines in positions 170 and 
173 have been shown to be not required for multimerization (279).  
The mechanism leading to the NSP5 phosphorylation in infected cells is not yet 
completely elucidated. There are reports indicating that NSP5 expressed in bacteria, 
and thus free of contaminating kinases of mammalian cells, purified and incubated 
with [γ-32P]ATP has a low level of auto-kinase activity in vitro, associated with a 
recently reported ATPase activity (13, 26, 290). However, the auto-kinase property is 
unlikely to be sufficient to generate a fully phophorylated state of NSP5 and the 
conversion from hypo- to hyperphosphorylated isoforms of NSP5 seems to be 
mediated by cellular casein kinase-like enzymes (43, 84, 87). Furthermore, a viral 
cofactor appears to be required to generate all the phosphorylated isoforms in the 
relative amounts observed in infected cells (3, 228). For instance, by coexpression 
experiments in uninfected cells NSP2 has been shown to be able to up-regulate the 
NSP5 hyperphosphorylation, most likely as a consequence of the interaction between 
the two proteins (2) and certainly not because of the NTPase activity of NSP2 (46). 
Thus, it is clear that many factors are involved in the hyperphosphorylation of NSP5, 
which appears to be a multi-step process (84). By the use of deletion and point 
mutants and siRNAs against the cellular kinase CK1α, it has been shown that the 
phosphorylation of serine 67 by CK1α and an intact C-terminus (84, 256, 279) are 
both required for initiating the cascade of NSP5 hyperphosphorylation (43, 84). 
Moreover, in the absence of other viral proteins, certain NSP5 deletion mutants 
lacking either the first 33 amino acids (Δ1) or the amino acids 81-130 (Δ3) can 
undergo hyperphosphorylation (87), probably because of an intact C-terminus able to 
multimerize and a conformation where serine 67 is available for phosphorylation; in 
addition, in the absence of other viral proteins, a mutant in which serine 67 is 





hyperphosphorylated (84). It has then been proposed that the interaction with NSP2 
induces a conformational change of NSP5 that renders serine 67 exposed and 
available for phosphorylation, but it was not predictable whether this phosphorylation 
occurs before or after NSP5 multimerization (84). Interestingly, and surprisingly, 
structural studies showed that a NSP5 mutant lacking the first 65 amino acids and the 
last 10 amino acids (NSP566-188) interacts with NSP2 as a dimer, and more precisely 
four NSP5 dimers bind to one NSP2 octamer (139). Since NSP566-188 was not 
expected to be able to dimerize because of the deletion at the C-terminus (279) and 
since it is known that NSP2 does not induce the hyperphosphorylation of mutants 
having a deleted C-terminus (96), it is possible that NSP5 needs to multimerize in 
complexes larger than dimers to be hyperphosphorylated.  
Several lines of evidence indicate that an intact C-terminus is necessary but not 
sufficient not only for NSP5 hyperphosphorylation, but also for VLS and viroplasm 
formation: (i) NSP5 and NSP2 coexpressed in uninfected cells form VLS, but neither 
NSP5 expressed alone nor a NSP5 deletion mutant lacking the 18 C-terminal amino 
acids coexpressed with NSP2 do (85, 96); (ii) an NSP5 mutant containing only the 
68 C-terminal amino acids cannot form VLS when expressed alone, but when it is 
transiently expressed in infected cells, it is recruited into viroplasms, probably as a 
consequence of its interaction with viral NSP5 (85, 87); (iii) in addition to an intact 
C-terminus, the presence of the 33 N-terminal amino acids was shown to be required 
for VLS formation in coexpression experiments with NSP2 (85); (iv) according to 
anticipated data in the Discussion section of ref. (13), the mutant NSP566-188 does not 
form VLS with NSP2 despite interacting with it. This latter observation negates the 
necessity of an interaction between NSP2 and NSP5 for VLS formation (85) and is 
consistent with the finding that N-tagged derivatives of NSP5 can form VLS when 





terminal amino acids of NSP5 may serve to promote viroplasm assembly through the 
mutual recognition, the multimerization and the consequent recruitment of already 
formed NSP5-NSP2 complexes (13); in this view, the contribution of NSP2, or of the 
tagging at the N-terminus, might consist in inducing a conformational change of 
NSP5 that renders the C-terminus accessible for the homo-multimerization of many 
NSP5 molecules. However, the role of NSP2 and the NSP5 N-terminus in VLS 
formation remains still little defined.  
A controversial issue is the possibility of a link between NSP5 hyperphosphorylation 
and VLS or viroplasm formation: despite the frequently observed correlation between 
the hyperphosphorylation status of NSP5 and the viroplasm/VLS formation (96, 
228), supported also by the fact that tagging NSP5 at the N-terminus renders the 
protein both capable of forming VLS by itself (190) and hyperphosphorylated (44), 
most evidence indicate that hyperphosphorylation is not required for viroplasm/VLS 
formation: in fact, (i) in vivo inhibition of phosphatases in cells transfected with an 
NSP5 encoding plasmid results in a fully phosphorylated NSP5, but not in VLS 
formation (27); (ii) NSP5 deletion mutants that are not phosphorylated are recruited 
into viroplasms of infected cells (87); (iii) an siRNA against CK1α, the kinase 
involved in the phosphorylation of serine 67, inhibits NSP5 hyperphosphorylation, but 
not viroplasm formation (43). It has been proposed that NSP5 hyperphosphorylation 
has a role in viroplasm maturation and possibly in replication since its inhibition by an 
siRNA against CK1α results in an altered viroplasm shape and a moderate decrease 
in dsRNA synthesis (43). Viroplasms have also been proposed as sites where NSP5 
is protected by the action of cellular phosphatases (27) and NSP5 
hyperphosphorylation would then be guaranteed by viroplasm/VLS formation. 
Hyperphosphorylation and viroplasm/VLS formation may also be independent 





It has recently been reported that calcium regulates VLS formation: in the absence of 
calcium VLS cannot form, but when two tandem DxDxD motifs located upstream and 
adjacent to the predicted C-terminal helix of NSP5 are mutagenized, VLS can form 
constitutively even in the absence of calcium (256). This is in agreement with the role 
of regulator of viroplasm maturation proposed for NSP4 (21), the viral protein that 
modifies the calcium homeostasis in rotavirus-infected cells. 
With regard to the interaction of NSP5 with NSP2 (2, 85, 96, 139, 228), the N-
terminus and the C-terminus of NSP5 have been initially identified by yeast two-hybrid 
and coimmunoprecipitation studies as the regions essential for binding (85). 
However, the cryo-EM structure of the complex NSP2-NSP566-188 suggests that those 
regions may also be dispensable (139). In the same report, a competition between 
NSP566-188 and RNA for binding to NSP2 is described, suggesting a role for NSP5 
in regulating NSP2-RNA interaction during replication and/or packaging (139). 
Apart from interacting with NSP2, NSP5 also interacts with VP1 (2, 8) and VP2 (23), 
but the role of these interactions is at present completely obscure. As already 
mentioned, coexpression in insect cells of NSP5 and a deletion mutant of VP2 
lacking the 92 N-terminal amino acids leads to the formation of a few and large 
inclusion bodies, into which VP6 is also recruited when coexpressed with the other 
two proteins (23). However, NSP5 was shown to affect the stability of VLPs formed 
by VP2 and VP6 and VP6 to hinder the NSP5-VP2 interaction (23). This suggests a 
competition between NSP5 and VP6 for binding to VP2.  
An interaction of both NSP5 and NSP2 with tubulin has been found, suggesting a 
role for the two nonstructural proteins in anchoring viroplasms to microtubules (42). 
NSP6 
NSP6 is the smallest nonstructural protein of rotavirus, is encoded in an alternative 





and localizes in viroplasms (178, 238). It has a high rate of turnover, being 
completely degraded within two hours of synthesis (238). Some rotavirus strains of 
group A and all strains of group C do not encode NSP6 (115, 148), and the group 
A OSU strain encodes a truncated version of NSP6 (111), suggesting that this protein 
is not essential for the viral replication cycle. This view is strengthened by the fact that 
a cell line expressing NSP5 from OSU strain, and thus a truncated and possibly non-
functional NSP6, transfected with an siRNA against NSP5 from SA-11 strain and 
infected with SA-11 strain, shows a wild-type phenotype of viral infection because of 
the complementation ability of the OSU-derived NSP5 and despite the absence of a 
full-length NSP6 (45). NSP6 was found to interact with the 35 C-terminal amino 
acids of NSP5, and since the removal of the 10 C-terminal amino acids from NSP5 
abolishes the interaction, it has been proposed that NSP6 has a regulatory, but not 
essential, role in the self-association of NSP5 (279). However, the NSP5-NSP6 
interaction has been described only in transfected cells and could never be detected 
in infected cells (279). Recently, it has been shown that similarly to NSP5, NSP6 has 
an unspecific affinity for both ss and dsRNA (238). 
 




Most details of the rotavirus replicative cycle have been obtained from studies 
of cell culture-adapted rotavirus strains infecting monkey kidney cells (MA104). 





new data, sometimes in contrast with those derived from MA104 cells, are emerging 
from infection of differentiated human intestinal cell lines (Caco-2) (91).  
The studies with MA104 cells allowed to define some general features of rotavirus 
replication (91): 
- replication is totally cytoplasmic; 
- cells do not contain enzymes to replicate dsRNA, they are supplied by the 
virus; 
- free dsRNA or free negative-strand ssRNA are never found in infected cells; in 
fact, dsRNA segments are formed within nascent subviral particles and once 
the negative strand is synthesized, it remains associated with the positive-
strand; 
- levels of intracellular calcium are crucial to allow virus assembly and integrity. 
Based on all data so far collected, a general description of the replicative cycle can 
be provided (Fig. 8). After entry into the host cell the virion loses the outer layer to 
become a DLP. At this stage the viral RdRp, VP1, transcribes plus-strand RNAs, which 
are capped but not polyadenylated, and are extruded from the viral particle into the 
cytoplasm. This single plus-strand RNA functions as both: 
- messenger RNA for the synthesis of viral proteins; 
- template for the synthesis of the dsRNA genome segments (“replication”). 
Once critical amounts of viral proteins are synthesized, viral proteins accumulate in 
cytoplasmic inclusion bodies called “viroplasms”, which appear early (2-3 hours) 
after infection and are considered to be sites of the synthesis of dsRNA and assembly 
of progeny DLPs. Subviral particles assembled in viroplasms bud through the 
membrane of the endoplasmic reticulum (ER) acquiring a transient envelope. Budding 
is mediated by the NSP4 molecules incorporated into the ER, which function as 





VP4-VP7 layer. TLPs are released either by cell lysis or by a non-classical, Golgi-
independent, vesicular transport involving interaction with lipid “rafts” near the plasma 
membrane and not resulting in extensive cytopathic effect (91). 
The details, the most plausible hypothesis and the controversial findings about the 





4.2. CELL ATTACHMENT AND ENTRY 
 
Rotavirus attachment to target cells and the following entry are a complex and 
not yet entirely elucidated process involving sequential interactions of VP4 and VP7 
with different cellular receptors.  





Although VP7 has been shown to contribute to the attachment (102, 248, 306), VP4 
plays a major role in this preliminary phase of cell entry (146, 167). The first event 
involving VP4 (88KDa) is its cleavage by intestinal trypsin into two fragments, VP5* 
(60KDa) and VP8* (28KDa), which remain associated in the virion (94, 98). 
However, this cleavage does not appear to be essential for cell binding (59, 144), 
rather, it has been associated with cell entry (see below). Sialic acid (SA) was the first 
rotavirus receptor identified as crucial for cell attachment based on hemagglutination 
of red blood cells induced by some rotavirus strains (17, 98). VP8* was recognized 
as the functional component of rotavirus hemagglutinin (98, 100). However, since 
many rotavirus strains, including all human rotaviruses, were shown to initiate 
infection independently of sialidase treatment of cultured cells and were not believed 
to bind to SA (58, 179), rotavirus strains were classified in two categories: SA-
dependent and SA-independent. This distinction is now considered imprecise. In fact, 
there is increasing evidence that several sialidase-insensitive strains bind to sialic 
acids located internally within oligosaccharide structures, and thus not accessible to 
sialidases, or to sialic acids modified and thus resistant to sialidase treatment (71, 
126, 127, 140). Therefore, a classification only based on the sensitivity of infectivity 
to sialidase treatment is preferable. This idea is also supported by x-ray 
crystallographic studies of complexes formed by sialic acid derivatives and purified 
VP8* derived from both sialidase-sensitive and sialidase-insensitive strains (28, 82). 
A second receptor shown to be involved in rotavirus attachment, and possibly 
penetration (57), is α2β1 integrin, which is bound by VP5* through the sequence 
DGE (120, 121, 304, 305). 






- the heat shock cognate protein 70 (Hsc70), whose binding with VP5* may 
modify the conformation of the virus particle to help entry (124, 216, 303); a 
recent report suggests also an involvement of VP6 in interaction with Hsc70 
(123); 
- αvβ3 integrin and αxβ2, which are bound by VP7 (120, 122, 125); 
- α4β1 and α4β7 integrins: since neutralizing monoclonal antibodies against 
both VP5* and VP7 inihibit binding of rotavirus to these integrines, they may 
be bound by both VP5* (possibly through its YGL sequence) and VP7 (119). 
The internalization process occurs through a not completely elucidated mechanism. It 
has been demonstrated that (91): 
- it requires active cellular processes because it does not take place at 4°C; 
- it does not depend on endosome acidification (as found for influenza viruses); 
- it is enhanced by trypsin cleavage of VP4, as trypsinased particles enter cells 
more quickly than non-trypsinased (7, 94). 
However, molecular details of cell entry remain unclear. Two pathways are proposed 
to be involved: direct penetration (144, 268) and a non-classical endocytosis. This 
latter would depend either on endocytic vesicles that maintain low Ca2+ levels (50) or 
on the presence of cholesterol on the cell membrane and on a functional dynamin, 
independently of both clathrin and caveolin (50, 251). Since the mechanisms of cell 
entry are not well defined, the role of trypsin cleavage also remains poorly 
understood. Trypsin has been found incorporated in TLPs in an inactive form and is 
activated in an environment containing low concentrations of Ca2+ (18), as might 
occur near the plasma membrane following cell binding. It has been proposed that 
trypsinization induces VP4 spikes to switch from a disordered to an ordered structure 
and that conformational changes of VP4 at a post-attachment stage allow sequential 





fragments deriving from trypsin cleavage of VP7 and VP4 were shown to be capable 
of disrupting membranes (47, 72, 245), allowing access of DLPs into the cytosol.  
The loss of VP4 and VP7 (uncoating) resulting from the cell entry represents a key 
event, as it triggers the emergence of transcriptionally active DLPs (see below). Many 
reports agree on a correlation between the uncoating process and a lowering of 
Ca2+ concentration at the membrane proximity (50, 61, 172, 245, 247), even if the 
details and the sequential order of the events leading to the access of uncoated 




Synthesis of full-length positive-strands from the negative-strands of the dsRNA 
genome (transcription) occurs after cell entry (primary transcription) and also when 
new DLPs are formed within viroplasms (secondary transcription) (91, 166, 265). The 
process is considered to occur in three stages (157, 158): 
- initiation, which consists in synthesis and capping of the nascent transcript (6-
7 nucleotides); 
- elongation, in which the transcript starts separating from the genomic template 
and nucleotidyl transfer proceeds; 
- translocation, in which the growing transcript pass through type I channels, to 
be extruded from the DLP. 
The transcriptase activity of the viral particle is activated in vitro by removal of VP4 
and VP7 through chelating agents or heat shock treatment (61, 264). Therefore, the 
uncoating process seems to be the essential event triggering primary transcription. 





infection when they are liposome-transfected into cells (16). It has to be noted that 
TLPs cannot be defined properly as transcriptionally incompetent, they rather contain 
a latent transcriptase activity: in fact, in vitro they can produce 5-7 nucleotide long 
capped mRNA fragments (157), suggesting that polymerase and capping enzyme 
are both functional in TLPs and that some structural properties related to the presence 
of the outer capsid interfere with elongation, and possibly translocation, of the 
transcripts. Many factors have been proposed to explain this inhibitory effect: 
conformational changes of VP6, induced in vitro by both VP7 and some anti-VP6 
antibodies (97, 156); a steric hindrance blocking the exit of nascent mRNAs through 
type I channels, as shown for VP7 (159); structural constraints arising from the 
geometry imposed by proteins of both the external and the intermediate layers (162). 
However, the details remain to be elucidated. 
Rotavirus contains all the necessary enzymatic machinery to synthesize complete 
capped mRNA transcripts within the core without the need for disassembly. Indeed, 
transcription occurs efficiently only when the transcriptionally competent particle is fully 
intact (158). This particle comprises VP1, the RdRp, VP3, which functions as a 
guanylyl-transferase and methylase, VP2 and VP6, whose mutual interactions maintain 
a spatial architecture needed for the transcriptase activity (48). The enzymatic 
activities of the transcriptionally competent particle have either been demonstrated 
biochemically or they are inferred because rotavirus transcripts made in vitro in the 
presence of S-adenosyl methionine (SAM) have a methylated 5’-terminal cap structure 
m7GpppGm (52, 164, 225), and transcription is inhibited by pyrophosphate (264). 
Since the template is a dsRNA, a helicase activity has been thought to be required to 
unwind the template, but that enzymatic property has so far not been demonstrated 





Cryoelectron microscopy studies indicated that transcription occurs near the 5-fold 
axes, where VP1 and VP3 are located, and that multiple newly transcribed RNAs 
pass through type I-channels and are released simultaneously from an actively 
transcribing particle (159, 234), confirming the fact that DLPs can transcribe 
concomitantly many different ssRNA molecules (264) and that the transcription 
process is continuous. However, the mechanisms driving the movement of the 
genome segments through the enzyme complex to allow repeated cycles of 
transcription remain unknown. 
As already mentioned, plus-strand RNAs deriving from transcription are extruded from 
the DLP into the cytosol, where they can be used either for the synthesis of viral 




Rotavirus mRNA transcripts are capped and not polyadenylated. These are 
two important peculiarities to be considered to understand how rotavirus uses the 
cellular translation machinery. The cap structure can be recognized by the cellular 
cap binding protein eIF4E, which promotes the association with the 40S ribosomal 
subunit. The eIF4E protein belongs to a complex called eIF4F, in which two other 
proteins are found: a helicase, which unwinds RNA secondary structures, and the 
scaffolding protein eIF4G, which binds the poly(A)-binding protein (PABP), in turn 
bound to the poly(A) at the 3’ end of eukaryotic mRNAs, thus approximating the two 
mRNA ends to ensure an efficient initiation of translation (237). This complex does 
not seem to be able to recruit PABP onto rotavirus mRNAs, not only because there is 





nonstructural protein, NSP3, is able to compete with PABP for binding to eIF4G 
(223, 224). Since NSP3 recognizes also the consensus sequence 5’-UGACC-3’ at 
the 3’UTR of viral mRNAs (74, 226, 227), this protein has been considered to be 
able to promote the circularization of rotaviral mRNAs, thus enhancing their 
translation (224). At the same time NSP3 hampers the translation of cellular mRNAs 
through its competion with PABP for binding to eIF4G (224) and concomitantly 
causes a translocation of the free PABP from the cytoplasm to the nucleus (192). 
NSP3 and eIF4G also interact with a cellular protein called RoXaN (Rotavirus X 
protein associated with NSP3) forming a ternary complex, whose role remains to be 
determined (292). However, despite a general agreement on the role of NSP3 in 
inhibiting translation of cellular proteins, its role in rotavirus mRNAs translation is still 
controversial: on one side it has been shown that NSP3 enhances translation of 
rotavirus-like mRNAs both in vivo and in vitro (289), on the other hand silencing of 
the expression of both NSP3 and eIF4G by siRNAs does not affect synthesis of viral 
proteins and may even increase the yield of viral progeny (191). The binding of 
NSP3 to viral plus-strand RNAs has been then proposed to protect viral mRNAs from 
degradation and/or to keep a pool of plus-strand RNAs in the cytoplasm available 
for translation (191). 
Interestingly, three additional viral proteins have recently been shown to be involved 
in inhibition of cellular protein synthesis: VP2, NSP2 and NSP5. They seem to be 
involved in phosphorylation of the α subunit of the translation initiation factor eIF2, an 
event that inhibits the translation of cellular mRNAs (192). However, further 
investigations are needed to demonstrate the details of their involvement. 
Most rotavirus proteins are synthesized on free ribosomes because of the absence of 
signal sequences for targeting to the ER. However, VP7 and NSP4 contain such 





the membrane of the ER. The signal sequence of VP7 is cotranslationally cleaved, 
whereas that of NSP4 is not (91). 
 
4.5. GENOME REPLICATION AND PACKAGING 
 
Rotavirus RNA replication and packaging represent one of the most 
unexplored and intriguing aspects of the replicative cycle. Its understanding would 
help in constructing reassortant rotaviruses and rotaviruses by reverse genetics and 
also be helpful for the further development of safe vaccines. 
As already mentioned, the newly synthesized viral plus-strand RNAs are used not only 
as transcripts for the synthesis of viral proteins, but also as templates for the synthesis 
of the complementary negative-sense strand RNA, leading to the emergence of 
dsRNA genome segments. This process is named “replication”. After replication, 
dsRNAs remain associated with subviral particles (complexes separable by 
sedimentation through sucrose or CsCl gradients), suggesting that free dsRNA is not 
found in the cytoplasm of infected cells (91). 
The proteins involved in replication have been studied by analysis of subviral particles 
capable of completing nascent negative-strand synthesis in vitro (Replication 
Intermediates or RI), by cell-free systems supporting the synthesis of viral RNAs from 
exogenous RNA templates and by the analysis of production of dsRNAs in infected 
cells transfected with small interfering RNAs (siRNAs) against specific viral RNA 
segments: 
- Replication Intermediates (RI): VP1, VP2, VP3 and the nonstructural proteins 
NSP2, NSP3 and NSP5, together with attached RNAs, have been identified 
in the minimum particle purified from infected cells with replicase activity 





replication. By immunoprecipitation from extracts of infected cells with a 
monoclonal anti-NSP2 antibody, an active replicase complex has been 
reported, which contained VP1, VP2, VP3 and VP6 but lacked NSP1, NSP3 
and NSP5. This complex was able to complete the synthesis of nascent 
negative-strand RNAs, but not to use exogenous RNAs as templates (5). 
- Template-dependent cell-free replication systems (55, 208): such systems 
containing only the structural proteins of the core, derived from either virions or 
baculovirus recombinants, showed that VP1 and VP2 are necessary and 
sufficient to provide replicase activity in vitro (212, 308). However, the levels 
of replicase activity were significantly higher in the presence of VP3 (212, 
308). These observations supported the view that nonstructural proteins are 
not essentially required for replicase activity, but did not rule out that they can 
increase replication efficiency in vivo or may have a role in genome 
packaging. 
- Experiments with siRNA and analysis of dsRNA production: such experiments 
confirmed the involvement of VP1, VP2, NSP5 and NSP2 in viral RNA 
replication (45, 166, 261, 262) and showed that silencing of NSP3 (191), 
NSP4 (262) and VP7 (261) does not reduce the amounts of replicated 
dsRNAs. 
All viral proteins found in RI, with the exception of NSP3, were also found in 
perinuclear nonmembrane-bound electron-dense cytoplasmic inclusion bodies called 
viroplasms, where VP6 was detected in addition (219, 220, 241) (Fig. 9). These 
inclusion bodies, representing accumulations of viral proteins and RNA, appear early 
(2-3h) after infection and are considered sites of viral RNA replication and DLP 
assembly based on their protein composition and on electron microscopy analysis 





Viroplasms were also shown to be sites of transcription, possibly mediated by the 
newly assembled DLPs and therefore termed secondary transcription (261). Two 
nonstructural proteins, NSP5 and NSP2, are considered essential for the formation of 
these inclusion bodies: they were shown to be able to form VLS when coexpressed in 
uninfected cells (96) (Fig. 9) and suppression of their expression in infected cells 
abolished viroplasm formation, viral RNA replication and production of infectious viral 
progeny (45, 166, 261, 285). 
Beyond the involvement of the indicated proteins in replication, the experiments with 
siRNAs revealed another important aspect of genome replication. Since the viral 
transcripts function both as messengers and as templates of genome synthesis, it was 
expected that siRNAs directed to transcripts encoding proteins not involved in 
replication, like VP4 and VP7, would impair the synthesis of both the protein and the 
corresponding dsRNA. However, it has been reported that siRNAs directed to VP4 
and VP7 allowed the synthesis of regular amounts of all eleven genome segments, 
despite the synthesis of the target protein was almost completely ablated (67, 165, 
261). This led to the idea of two separate pools of viral plus-strand RNAs, one used 
for translation and the other for replication. How this physical separation occurs and 
may be maintained is not clear. Viroplasms might create a protective environment for 
replicating plus-strand RNAs or the association with some viral RNA-binding proteins 
might make them inaccessible to the cytoplasmic RNA interference machinery. With 
this regard, it has been shown that a labelled rotavirus-like plus-strand RNA 
transfected in cells one or five hours after infection was not recruited into viroplasms, 
leading to the conclusion that pathways for delivering plus-strand RNAs from cytosol 
to viroplasms do not exist (261). According to these data, a model was suggested 
for which DLPs would function as nucleation sites for viroplasm formation following the 





in viroplasms exceeds the binding capacity of the RNA binding proteins, the 
transcripts would leave viroplasms and be used for a further synthesis of viral proteins 
(261). The suggested lack of pathways that transport plus-strand RNAs to viroplasms 
would explain the failure of numerous attempts to construct a recombinant rotavirus 
(91). Whilst the insertion of an exogenous viral RNA into the viral progeny has 
recently been achieved (see description of the system in chapter 5) (150), the very 
low efficiency of recovery of recombinant virus suggests that the accessibility of 
exogenous RNAs to viroplasms is limited. 
Except for VP1, the functions of individual proteins involved in viral RNA replication 
remain controversial and obscure. Apart from functioning as a transcriptase, VP1 
catalyzes the synthesis of viral minus-strand RNAs after specific recognition of the 
template at both the 5’ and 3’UTRs (280, 281). More in detail, it has been shown 
that the 5’ end contains a specific recognition signal associated with the G2 residue 
of the 5’-consensus sequence and that the 3’ end contains signals in both the 
conserved and nonconserved regions (280, 281). The binding of VP1 to these sites 
is essential to promote replication, possibly stabilizing the putative cyclization of the 
template in a panhandle structure (281). On the other hand, in replication assays 
recombinant VP1 is not sufficient to promote minus-strand synthesis, unless VP2 is 
added (280).  
VP2, which has a strong affinity for the single-strand template but less for the dsRNA 
(212), and binds RNA in a nonspecific manner (209), must have a role linked with 
binding to the template, to VP1 and possibly to VP3 (307). The fact that dsRNA 
synthesis in replication assays with recombinant VP1 and VP2 was maximal when the 
ratio between the two proteins was 1:10 indicated that replicase activity requires 
structures similar to those observed at the vertexes of the core, suggesting an 





this context remains still undefined. Assays performed with recombinant VP1 and VP2 
also showed that the order of interaction of these proteins with the template affects the 
efficiency of formation of active replicase complexes, suggesting that their formation 
in vivo would start in an environment free of VP2 (291).  
Without recognizing any specific signal in the template and through its affinity to 
VP1, VP2 and/or RNA, VP3 might have the role of increasing the rate at which 
replication complexes are assembled (in addition to its function of capping enzyme 
during viral transcription)  (209, 212, 286). 
As already mentioned, the nonstructural proteins NSP5 and NSP2 have an important 
role in forming viroplasms but do not seem to be essential for the replicase activity. 
However, they might increase or regulate the replication process or have a role in 
genome packaging.  
Because of its ssRNA binding and helix destabilizing properties, the octamer NSP2 
has been proposed as a platform that organizes replication complexes and unravels 
any secondary structure in positive-sense RNA templates in preparation for the dsRNA 
synthesis (272). How NSP2 distinguishes between viral and cellular RNAs is still an 
open question. RNA binding seems to induce a conformational change in NSP2 
(139, 255), which might have a role in regulating interactions with other viral 
proteins, such as VP1 (145) or NSP5 (2, 96). Although the role of the enzymatic 
activities of NSP2 (NTPase, RTPase, NDP kinase; see chapter 3 for details) is still 
unclear, it has been proposed that NSP2 acts as a molecular motor providing the 
energy deriving from hydrolysis of NTPs for genome replication and/or packaging 
(138, 272) and maintaining a pool of nucleotides in viroplasms for RNA synthesis 
and for processes requiring ATP (i.e. transcription or RNA packaging) (151). 
Interestingly, an inhibitory role for NSP2 in the formation of the replication initiation 





In detail, NSP2 was shown to interfere not with the binding of VP1 to the template, 
but with the function of VP2, possibly as a result of competition for RNA binding 
(291). 
The role of NSP5 in RNA replication and packaging is even more obscure than that 
of NSP2: it has recently been shown that a truncated form of NSP5 competes with 
RNA for binding to NSP2 (139), suggesting that NSP5 might have a regulatory role 
in the RNA binding activity of NSP2. Moreover, based on the description of an 
interaction between NSP5 and VP2 (23), it has been suggested that NSP5 may act 
as a physical adapter between NSP2 and VP2. However, a strong interaction 
between NSP5 and the polymerase VP1 has recently been observed [described in 
this thesis and (8)], indicating the need of further studies to investigate new possible 




FIG. 9:  Localization of rotavirus NSP2 and NSP5 in 
viroplasms and VLS. The two proteins were detected 
by immunofluorescence microscopy using antibodies 
specific for NSP2 or NSP5 as indicated, in cells 
infected with SA11 rotavirus (a, b), transfected with 
either NSP2 (c, d) or NSP5 (e, f), or cotransfected with 
NSP2 and NSP5 (g, h). From Fabbretti et al, 1999. 





Genome packaging is a selective process capable to guarantee the presence of all 
eleven genome segments in equimolar amounts in every newly assembled viral 
particle. Signals and mechanisms driving the assortment of the genome segments are 
unknown. The requirements for packaging are rather complex, as indicated by in 
vitro replication assays: if VP1 and VP2 are sufficient to provide replicase activity, 
they are not to package the newly synthesized dsRNAs (212). Secondary structures 
of the eleven dsRNA segments and/or nonstructural proteins may be of importance 
for packaging.  
Several models have been proposed for describing genome replication and 
packaging (213): 
- precore precursor model: a precore consisting of viral RNA, VP1 and VP3 
would function as a nucleation site for the binding of VP2 to form a core. This 
model is based on the isolation from infected cells of precores without 
replicase activity and containing RNA, VP1 and VP3 (104).   
- empty capsid precursor model: empty cores (VP1, VP2, VP3) would be first 
made and would be filled with RNA through a “packaging motor” formed by 
nonstructural proteins (e.g. NSP2, see above). This model is based on the 
ability of capsid proteins to self-assemble into empty virus-like particles (VLPs) 
able to support RNA replication (308) and on data obtained with a bacterial 
dsRNA virus, the bacteriophage phi6. 
- simultaneous encapsidation and capsid assembly model: each RNA-VP1-VP3 
complex would associate with a specific RNA segment and attract VP2, 
which would form pentamer subunits; interactions between RNAs of the 
different pentameric units would then induce the formation of cores; structural 
changes of VP2 after pentamer-pentamer binding may activate replication. 





the precore precursor model for the formation of functionally separate 
pentameric units before core formation (234). 
Further studies are needed to clarify which model is correct and if and how they may 
need to be modified. 
 
4.6. VIRUS MORPHOGENESIS 
 
Initial assembly of viral progeny starts in viroplasms, where new DLPs are 
synthesized and viral genome segments are sorted and packaged through a still 
unknown mechanism. During the course of viral infection, viroplasms mature showing 
an increase in size and a decrease in number, suggesting a continued accumulation 
of proteins, RNA and newly formed viral particles and a fusion process among 
different viroplasms (85). It has been reported that silencing expression of the 
nonstructural protein NSP4 leads to a defect in viroplasm maturation, with a 
concomitant maldistribution of viroplasmic proteins, and to a decreased assembly of 
packaged particles (262). This suggested a role for the nonstructural protein NSP4 in 
linking the process of genome packaging and capsid morphogenesis. With this 
regard, it has been reported that part of NSP4 is distributed in vesicles throughout the 
cytoplasm, colocalizing with the autophagosomal marker LC3 and in association 
with viroplasms (21). Therefore, these vesicles have been proposed as a lipid 
membrane scaffold for the formation of large viroplasms by recruiting early viroplasms 
and also as regulators of genome packaging and transcription (through NSP4 
association with VP6) (21). Furthermore, a role for NSP4 in facilitating the assembly 
of VP6 on the top of cores has been suggested by the fact that well-defined particles 
are apparent only at the periphery of viroplasms (181, 218, 230) and that purified 





However, silencing NSP4 expression still allows DLPs formation, even with a lower 
yield, and rather causes an accumulation of empty DLPs, confirming the hypothesis of 
a role of NSP4 in linking genome packaging and morphogenesis rather than in 
regulating the VP6 assembly on cores (165, 262).    
Once newly packaged DLPs are formed, rotavirus morphogenesis proceeds through a 
complex process consisting of several steps:  
- DLP budding into the ER; 
- acquisition of a transient envelope; 
- loss of the transient envelope and formation of the outer capsid layer; 
- TLP release from the host cell. 
The first step is mediated by the interaction of VP6 present on the surface of newly 
synthesized DLPs with NSP4 molecules localized in the ER membrane to act as 
intracellular receptors for DLPs (9, 19). The affinity between the cytosolic (C-terminal) 
tail of NSP4 and VP6 drives this interaction (180, 275-277). VP7 and VP4 do not 
seem to have a function in the transit of DLPs into the ER, because in their absence 
DLPs can still bud into the ER (67, 165). However, they oligomerize with NSP4 
forming a heterotrimeric complex (170), which may play a role in the following step, 
when a transient envelope containing all three proteins is acquired (229). When VP4 
is silenced, TLPs are still formed, although without spikes and less infectious, 
suggesting that VP4 does not have an essential role at this stage (67). By contrast, 
silencing the expression of VP7 impairs TLP formation (261) and leads to the 
accumulation of enveloped particles, indicating a role for VP7 in the removal of the 
lipid membrane from particles maturating in the ER (165, 261). NSP4 glycosylation 
was also proposed to be critical at this stage (69, 218). However, the mechanisms 
underlying the loss of the envelope and the following correct assembly of capsid 





in the ER is a calcium-dependent process. In fact, experimental disruption of calcium 
gradients, in particular inhibition of the endoplasmic reticulum calcium pump (SERCA 
pump), decreases the production of infectious particles significantly with the 
concomitant accumulation of enveloped particles (181, 230, 258, 259); on the 
other hand, inhibition of the SERCA pump at late infection times induces the 
disassembly of already matured particles within the ER (246). During rotavirus 
infection the plasma membrane permeability to calcium increases and consequently 
cytosolic calcium concentration and calcium sequestering into the ER rise (181). 
siRNA experiments have shown that changes in calcium homeostasis are mediated 
mainly by NSP4 and to a lesser extent by VP7 (302). This is consistent with the 
evidence of higher cytosolic calcium levels in uninfected cells expressing recombinant 
NSP4 (22, 77, 278) and with the inhibition of the calcium permeability of the 
plasma membrane by the use of tunicamycin, an inhibitor of the ER N-linked 
glycosylation involving both rotavirus glycoproteins NSP4 and VP7. However, VP7 
glycosylation does not seem to be essential, as rotavirus strains with a non-
glycosylated VP7 exist which are capable to produce fully infectious particles (91). 
How NSP4 alters the calcium homeostasis is currently unknown: it might destabilize 
the plasma membrane directly, act as a viroporin or interact with cellular proteins to 
exert its permeabilizing activity. The exact role of an environment rich in calcium for 
virus morphogenesis is not known: it has been proposed that it triggers the lateral 
interaction of VP7 molecules forming a tighter layer able to interact with VP6 and 
concomitantly remove lipids and NSP4 (165). In fact, among the consequences of 
an experimental calcium depletion in the ER, there are the alteration of VP4-VP7-
NSP4 heterotrimers (230) and a block of VP7 trimerization (80). In addition to 
calcium concentrations, other factors are essential for a proper virus assembly in the 





PDI (protein disulfide isomerase), grp78, calnexin and reticulin, which have been 
shown to be essential for the correct folding of NSP4 and VP7 (173, 184, 186). 
A controversial issue is how and when VP4 is inserted into newly formed viral 
particles. VP4 assembly was initially thought to occur concomitantly with VP7 in an 
NSP4-dependent process within the ER (170). However, in infected Caco-2 cells VP4 
was not found to colocalize with ER-markers (69), and was detected in association 
with raft-type membrane microdomains (RTM), which are absent in the ER and were 
shown to be involved in targeting rotavirus particles to the cell surface (66, 252). 
Moreover, treatment of infected Caco-2 cells with tunicamycin, a drug blocking 
enveloped particles in the ER, did not show any effect on VP4 localization, trafficking 
and association with rafts (69). Therefore, it has been proposed that VP4 is added to 
particles in a an extra-reticular compartment after removal of the transient envelope 
(69). In addition, it has been reported that VP4 can reach the plasma membrane 
through the microtubule network independently of the presence of other viral proteins 
(196). However, in MA104 cells both siRNAs against VP4 or NSP4 and 
tunicamycin treatment significantly reduce the targeting of VP4 to rafts suggesting that 
association of VP4 with viral particles may occur in the ER (65). Moreover, the in vitro 
recoating of DLPs requires that VP4 is added before VP7 to obtain infectious TLPs 
(283), which suggests the need in the ER of VP4 or of DLPs previously coated by VP4 
for a correct assembly. It has then been proposed that two pools of VP4 exist, one 
associated with particles in the ER and the other independently localized at the 
plasma membrane (65). Interestingly, it has been shown that there are significant 
differences in raft composition and in VP4 association to rafts in Caco-2 and MA104 
cells, which might in turn imply differences in virus assembly and release in the two 
cell types (68). These date indicate the importance of using a model that is as similar 





In conclusion, further studies are needed to elucidate location and timing of VP4 
assembly into newly formed viral particles. 
 
4.7. VIRUS RELEASE 
 
Another still unclear issue is the pathway used by rotavirus to leave the host 
cell: using MA104 cells, rotavirus was initially believed to exit by cell lysis (4, 195); 
afterwards, studies in polarized Caco-2 cells showed that rotavirus is released almost 
exclusively at the apical pole through a non-conventional vesicular transport that 
bypasses the Golgi apparatus and lysosomes (142). This process occurs in the 
absence of cell lysis, which fits the histopathological data found in vivo (142). 
Assuming that VP4 is assembled in the ER and that both VP4 and NSP4 have a role 
in virus release, the demonstrated associations of these proteins with rafts, actin 
and/or microtubules might be critical at this stage. More in detail, VP4 association 
with rafts (66, 252) might be mediated by the N-terminal galectin-like domain of VP4 
that would confer the same capacity of galectin-4 of using the “nonclassical secretory 
pathway” (68, 198); furthermore, VP4 might account for the apical release of 
progeny virions through binding to actin bundles of the brush border of cells, which 
causes a dissolution of apical microvilli (105, 106). Another report suggests that 
NSP4 contributes to the polarized virus release by stiffening the basolateral actin 
network in a calcium-dependent manner, through decreased phosphorylation of the 
actin remodelling protein cofilin (20). However, the signals directing particles formed 
in the ER to the nonclassical secretory pathway are unknown. In the conventional 
secretion pathway the cargo proteins transit from the ER to the Golgi apparatus 
through a vesicle-mediated transport system that constitutes the so called ER-Golgi 





usually recycling among ER, ERGIC and Golgi: ERGIC-53 and β-COP (297). 
Increasing evidence suggest participation of the ERGIC in rotavirus maturation, 
because NSP4, VP4 and VP7 were all found in this compartment (65, 187, 297). In 
addition, the overexpression of NSP4 in transfected cells as well as natural rotavirus 
infection change the distribution of ERGIC-53 from a juxtanuclear vesicle-like pattern 
to a more dispersed one (65, 297). It has then been proposed that at some stages 
organelles containing ERGIC-53 and rotavirus proteins exit the traditional secretory 
pathway and do not reach the cis-Golgi (65). Furthermore, in transfected cells NSP4 
was found to be responsible for blocking trafficking of transport vesicles from the ER 
to the Golgi apparatus through its association with microtubules (297). Since NSP4 
localizes in lipid rafts (66, 252), can bypass the Golgi apparatus to reach the 
plasma membrane (21, 267) and binds to caveolin-1 (a protein component of the 
caveolae, a subset of lipid rafts functioning as vesicular carriers that mediate vesicle 
formation, docking and fusion) (182, 204, 267), it is possible that during rotavirus 
maturation a fusion event between vesicles containing NSP4 and raft vesicles 
containing VP4 occurs, as already proposed in a model by Delmas and colleagues 
(70). Indeed, a contribution of NSP4 in rotavirus raft association has been 
demonstrated by silencing NSP4 expression (65). However, to elucidate the 
molecular details of virus release, further studies are needed. 
 
5. PATHOGENESIS, ILLNESS, IMMUNE RESPONSE AND VACCINES 
 
Rotaviruses replicate in the non-dividing mature enterocytes in the middle and 
upper region of the small intestinal villi: virus infection causes mild lesions and mild 
inflammation, but the damage to the enterocytes results in villous atrophy, 





lumen. This is the origin of the rotavirus-induced diarrhoea, whose severity depends 
also on the degree of Cl- secretion of the crypt cells that lye in the proximity of the 
infected enterocytes. The enteric nervous system may be involved since drugs 
blocking its functionality attenuate the rotavirus-induced diarrhoea (168). Analysis of 
different virus reassortants identified several viral proteins as being involved in 
virulence, in particular NSP4, which acts as an enterotoxin (as already discussed in 
chapter 3), but also VP3, VP4, NSP1, VP6, VP7, NSP2 and NSP3 (41, 91). Recent 
studies reported antigenemia and viremia in children with acute rotavirus 
gastroenteritis (29). However, systemic disease is rare, suggesting that spread of 
rotavirus may depend on a concomitant disease of different origin (91).  
After a short incubation of 1-2 days, clinical symptoms often start with vomiting 
followed by a watery diarrhoea lasting 4-7 days and rapid dehydration. Usually, 
only the first infection is symptomatic, afterwards the immune system provides 
protection against disease from re-infections. The primary infection usually elicits a 
predominantly homotypic humoral response, and subsequent infections elicit a 
broader heterotypic response. Humoral immunity, involving neutralizing antibodies 
against VP7, VP4 and antibodies against VP6, is believed to play an important role 
in protection, since a high level of serum IgA antibodies correlates with protection. A 
rotavirus-specific cytotoxic T cell response has also been detected, but its exact role in 
protection remains to be established (73, 91). 
Rotaviruses are transmitted by the fecal-oral route. Their resistance to physical 
inactivation and their ability to survive on various surfaces under different conditions 
may account for their rapid spread and their efficient transmission. Improvements in 
water or hygiene conditions in developing countries are thus thought to have little 
effect on rotavirus transmission. Therefore, safe and effective vaccines represent an 





August 1998, a rhesus rotavirus tetravalent vaccine (RotaShield®) was approved by 
the Food and Drug Administration (FDA): it contained a mixture of a rhesus monkey 
rotavirus of G3 serotype and three rhesus-human mono-reassortant strains carrying 
human G1, G2, and G4 genes and proteins. However, it was withdrawn in 1999 
because of a number of intussusception cases, which were epidemiologically 
associated with vaccine doses, particularly the first one (194). Following re-analysis 
of these cases, it emerged that the age at the time of vaccination rather than the 
vaccine itself was responsible for intussusception, suggesting that RotaShield may still 
be a valid option. Currently, two vaccines are licensed in many different countries: a 
pentavalent human-bovine reassortant live-attenuated, oral vaccine (RotaTeq®, 
developed by Merck Research Co.) and a monovalent vaccine derived from an 
attenuated human rotavirus (Rotarix, developed by GlaxoSmithKleine). The first was 
licensed for use in the USA in 2006 and the second has been approved in 90 
countries worldwide as of May 2007. Immunogenicity, safety and efficacy were 
demonstrated for both, but at present only based on vaccinations of children of 
industrialized and middle-income countries. Their efficacy in the poorest parts of the 
world still needs to be assessed, and relevant vaccine trials are ongoing. A lamb 
rotavirus strain, LLR, has been licensed in China as a live attenuated vaccine, but no 
clinical trial data are available at present. Although it is indisputable that an orally 
administrated rotavirus vaccine can protect against rotavirus diarrhoea, the risk of 
undesirable effects of live attenuated vaccines (clinical complications, revertance to 
virulence, genetic reassortment with co-circulating wild-type strains) remains a real 
possibility, underlining the importance of intensive post-marketing surveillance (73, 
91). Another major issue is the delivery of vaccines to the developing countries at 
costs that those countries can bear. In this regard, the WHO intends to provide 





to facilitate their delivering. Finally, special efforts in prevention are required in India, 
China and Indonesia, where one third of all rotavirus-dependent deaths occurs, since 
these countries depends almost entirely on vaccines manufactured domestically. 
 
6. INVESTIGATING INTERACTIONS AND FUNCTIONS OF 
ROTAVIRUS PROTEINS: THE CHALLENGE OF REVERSE GENETICS 
 
As it has become clear from the previous chapters, the investigation of functions 
and interactions of rotavirus proteins is mainly based on the following systems: 
- expression of recombinant proteins, individually or in combination, in insect 
cells using recombinant baculovirus or in transfected mammalian cells; 
- infection with temperature-sensitive mutants; 
- RNA interference; 
- in vitro replication systems; 
- yeast two-hybrid assays; 
In addition, an intracellular antibody-capture technology has been employed to 
investigate the role of NSP5 in the viral replication cycle (285). However, the ideal 
methodology would consist in studying the effect of defined mutations intentionally 
introduced into the viral genome segments and incorporated into infectious viral 
particles (reverse genetics). The problem is that members of the family Reoviridae 
have been shown to be very refractory to this approach for many years, and it is only 
recently that some systems have being proposed as useful and relatively simple tools 
for studying Reoviridae protein functions. The first strategy was developed for 
orthoreoviruses and was based on a complicated and never reproduced approach 
that combined infection with a helper virus and transfection with viral dsRNAs, viral 





sole reverse genetics system reported for rotavirus is also based on the use of a 
helper virus: briefly, a modified VP4 gene was cloned under the control of the T7 
promoter, and the resulting plasmid was transfected into cells previously infected with 
a recombinant vaccinia virus supplying the T7 RNA polymerase; one day after 
transfection, cells were infected with a helper virus of a strain different from that of the 
recombinant VP4; twenty-four hours later, cultures were harvested and the recovered 
viruses were amplified; selective pressure against the helper virus VP4 was provided 
by the use of two monoclonal antibodies that specifically neutralized the VP4 of the 
helper virus strain; recombinant viruses were then identified with a very low efficiency 
in the rescued viruses (150).  
Both the system proposed for orthoreoviruses and for rotavirus are limited by the need 
of a helper virus and by the inability of introducing desired mutations in each viral 
genome segment. Recently, recombinant reoviruses have been constructed through an 
entirely plasmid-based approach driving the expression of all genome segments by 
the recombinant T7 vaccinia virus system and avoiding both helper viruses and 
coexpression of equivalent wild-type proteins (147). A step further was the very recent 
achievement of a recombinant bluetongue virus (BTV) following lipofection of a 
complete set of in vitro synthesized plasmid-derived RNA transcripts (34). The success 
of the last two reverse genetics approaches indicates that the mRNAs of the high-
number segmented dsRNA viruses are infectious and that the establishment of a 
helper virus-independent reverse genetics system is theoretically achievable also for 
rotavirus. Therefore, efforts aimed at obtaining an easy and flexible method to 
introduce desired mutations into rotavirus genes are worthwhile and will benefit the 
understanding of regulatory sequence or protein functions, the comprehension of still 
obscure processes like genome segment reassortment and packaging and the design 
of new vaccines based on rationally attenuated recombinant viruses. 
 
 69
MATERIALS AND METHODS 
 
CELL CULTURE 
MA104 cells (embryonic African green monkey kidney cells) were grown as 
monolayers in Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal 
calf serum (FCS) (Invitrogen), 2mM L-glutamine and 50μg/ml gentamicin (Invitrogen). 
MA104 cells stably transfected with an NSP5-EGFP fusion gene were obtained by 
calcium phosphate procedure as described previously (3, 85) and cultured in DMEM 
complete medium supplemented with 500μg/ml geneticin (G-418, Invitrogen). 
 
VIRUS PROPAGATION 
The simian SA11 (G3, P6[1]), bovine RF (G6, P6[1]) and porcine OSU (G5, P9[7]) 
strains of rotavirus were propagated in MA104 cells as described previously (93, 
118). 
T7-recombinant vaccinia virus (strain vTF7.3) was propagated in HeLa cells as 
described by Fuerst et al. (101). 
Viral titres were determined by plaque assay (118). 
 
CONSTRUCTION OF PLASMIDS  
pT7v-NSP5 and pT7v-NSP2 were obtained as previously described (96). The NSP5 
gene was derived from the OSU rotavirus strain (Genbank accession number: 
D00474), the NSP2 gene from the SA11 strain (L04532). The VP1 and VP2 genes 





infected cells: viral RNA was extracted from 500μl of cell supernatant after complete 
cytopathic effect (CPE) had been reached. The cDNA was obtained by reverse 
transcription, using random hexamers (Sigma) and MuLV reverse transcriptase 
(Applied Biosystem) (136). Subsequently, the cDNA spanning the open reading 
frame (ORF) of VP1 was amplified in two portions by PCR with the couples of primers 
VP1/I for - VP1/I rev and VP1/II for - VP1/II rev, respectively (Table 2): the VP1/I 
amplicon reached from nucleotide 19 (first nt of the start codon of the coding region) 
to nucleotide 1322 and the VP1/II amplicon from nucleotide 1231 to nucleotide 
3285 (last nt of the stop codon). Both amplicons were subcloned into pGEM-T Easy 
vectors (Promega) following the supplier’s instructions and sequenced (MWG-Biotech, 
Ebersberg, Germany). The VP1/I amplicon was transferred into the pcDNA3 vector 
(Invitrogen) by cut with EcoRI restriction enzyme and insertion into the EcoRI-digested 
pcDNA3 vector. The correct orientation of the insert was checked by restriction 
analysis. Since in the overlapping region present in both VP1/I and VP1/II fragments 
(nt 1231-1322) there is a NsiI site, the VP1/II amplicon was cloned downstream the 
VP1/I fragment in the pcDNA3 vector using NsiI and XhoI restriction enzymes. In 
order to construct a histidine-tagged derivative of VP1/I and express the fusion 
protein in bacteria, the VP1/I amplicon was subcloned into the NcoI- and EcoRI-
digested Pet23d vector (Novagen) containing a sequence encoding the histidine tag. 
The pcDNA3-SV5-VP1 plasmid was obtained by inserting the gene encoding the 
SV5 tag (12 amino acid long) (263) upstream the VP1 cDNA. The oligonucleotides 
SV5/VP1 A and SV5/VP1 B (Table 2) were annealed and inserted into the HindIII- 
and KpnI-digested pcDNA3-VP1 vector. 
The cDNA spanning the ORF of VP2 was also amplified in two portions by PCR with 
the couples of primers VP2/I for - VP2/I rev and VP2/II for - VP2/II rev, respectively 





and sequenced. To obtain the complete VP2 cDNA, the VP2/II amplicon was cut 
with the HindIII and EcoRV restriction enzymes and inserted downstream of VP2/I in 
the pGEM-T Easy-VP2/I vector, previously cut with HindIII and EcoRI followed by end 
filling with the Klenow fragment of DNA polymerase. The complete VP2 cDNA was 
inserted into the pcDNA3 vector following the digestion with the KpnI and NotI 
restriction enzymes. The VP2/I amplicon (corresponding to the first 1078 nucleotides 
of the coding region of VP2) was transferred from the pGEM-T Easy-VP2(I) vector into 
a pGEX vector (GE Healthcare) to express in bacteria the first 357 amino acids of 
VP2 fused to GST. The pGEX-2T vector was preliminary modified with the insertion in 
the BamHI-EcoRI sites of an oligonucleotide derived from annealing of GEX-KpnI A 
and GEX-KpnI B oligonucleotides (listed in Table 2), in order to add the KpnI site and 
to insert VP2(I) in KpnI-EcoRI sites. 
The constructs coding for the deletion mutants of NSP5 pT7v-ΔN33 [termed Δ1], 
pT7v-Δd34-80 [Δ2], pT7v-Δd81-130 [Δ3], pT7v-Δd131-179 [Δ4], pT7v-ΔC18 [ΔT], 
pT7v-Δ4ΔT [Δ4ΔT], pT7v-ΔC48 [ΔC48], and the pT7v-(dom1EGFP4T) [1E4T], pT7v-
(EGFP-4T) [E4T], pT7v-(dom1EGFP) [1E] and pNSP5-EGFP vectors have been either 
reported or obtained as described previously (2, 86, 87, 96). The constructs coding 
for the phosphorylation mutants of NSP5 pT7v-NSP5/S67A and pT7v-NSP5a were 
obtained as described by Eichwald et al. (84).  
The pT7v-VP6 vector was obtained by cloning the VP6 gene (L33365) from SA11 
rotavirus-infected cells: the cDNA was obtained as described for VP1 and VP2 and 
the region spanning the open reading frame (ORF) of VP6 was amplified with primers 
VP6-for and VP6-rev listed in Table 2. The VP6 amplicon was cloned into the pGEM-T 
Easy vector, sequenced and cut with KpnI and EcoRV. It was then inserted into pT7v-
Δd81-130 [Δ3] vector previously digested with the same restriction enzymes in order 





The siRNA against the cellular kinase CK1α was as previously described by 
Campagna et al. (43). 
The vector pcDNA3-HA-PP2A/Cα encoding the 35KDa catalytic subunit of PP2A 
was constructed by cloning an N-terminally HA-tagged cDNA encoding PP2A/Cα 
















TAB. 2: Oligonucleotides used in cloning procedures. The portions of sequence corresponding 
to coding sequences are indicated in capital letters. The portions of sequence indicated in 
green and orange correspond to sites or to sticky ends of sites of the restriction enzymes used 
(indicated in brackets). Start codons and stop anticodons are underlined. The SV5 peptide 





PRODUCTION OF ANTIBODIES 
Anti-NSP5 and anti-NSP2 sera were produced by immunization of guinea pigs and 
mice and anti-VP7 serum by immunization of rabbits as described previously (2, 8, 
112). Serum anti-VP1 was produced by immunization of guinea pigs with the 
histidine tagged VP1/I protein fragment (amino acids 1-435). The protein was 
produced in the E. coli BL21 strain (GE Healthcare). Cultures were induced with 
3mM isopropyl-beta-D-thiogalactopyranoside (IPTG) for 3-4 hours at 37°C. Bacteria 
were centrifuged, and the pellet was washed with ice-cold PBS and resuspended in 
1.5% laurylsarcosin-PBS supplemented with 0.1μg/μl lysozyme, 1X CLAP cocktail 
(chymostatin, leupeptin, aprotinin, and pepstatin; 10μg/ml each, Sigma), and 5mM 
dithiothreitol (DTT) for sonication (6 times, 10 seconds, using the Soniprep 150 
instrument with the 9,5mm probe tuned at 23KHz). The supernatant was 
supplemented with 1% Triton X-100 in PBS (pH 7.2) and with Ni-NTA His-Bind resin 
(Novagen) equilibrated in 20mM imidazole in PBS. After rolling for 1 hour at 4°C, 
the sample was centrifuged at 1,000g for 5 minutes at 4°C, and the resin was 
washed with 10 volumes of 35mM imidazole in PBS. Elution was performed with 
two volumes of 250mM imidazole. The purified protein was quantified by staining 
with Coomassie brilliant blue after separation by PAGE and using Low Range MW 
(Bio-Rad) as standards. Guinea pigs were injected intraperitoneally (i.p.) with 100μg 
of protein and boosted 3 times (100μg every 15 days i.p.) in the presence of 
Incomplete Freund Adjuvant. Sera of the immunized guinea pigs were tested by 
Western blot on extracts of rotavirus-infected and uninfected cells.  
Anti-serum to VP2 was produced by immunization of guinea pigs and mice with the 
GST-tagged VP2/I protein fragment (amino acids 1-357). The protein was produced 
in the E. coli BL21 strain with a procedure similar to that used for histidine tagged 





for 4 hours at 25°C; the bacterial pellet was washed with ice-cold STE (10mM 
TrisHCl pH8, 100mM NaCl, 1mM EDTA pH8) and resuspended in STE 
supplemented with 0.1μg/μl lysozyme, 1X CLAP cocktail, 0.3-0.5% laurilsarcosine, 
and 2mM DTT for sonication; after addition of 1% Triton X-100 in STE, GST-VP2(I) 
was purified from bacterial lysates by affinity chromatography using GSTrap™ HP 
columns prepacked with Glutathione Sepharose™ High Performance medium (GE 
Healthcare) and was eluted under mild, nondenaturing conditions using reduced 
glutathione, following manufacturer’s instructions. Guinea pigs and mice were 
injected subcutaneously with 125μg and 40μg of protein, respectively, and boosted 
3 times every 15 days (with 50μg and 40μg of protein, respectively). Sera of the 
immunized guinea pigs and mice were tested by Western blot on extracts of 
rotavirus-infected and uninfected cells.  
 
TRANSIENT TRANSFECTION AND LABELLING WITH [35S]-METHIONINE OF 
MA104 CELLS 
T7 RNA polymerase expressed from a vaccinia virus recombinant (101) is used to 
increase the expression level of proteins encoded by the transfected genes 
engineered downstream the T7 promoter. Since the vaccinia virus replication cycle is 
cytoplasmatic, exogenous gene transcription and translation are coupled in the 
cytoplasm of the transfected cells. For transfection experiments confluent monolayers 
of MA104 cells in 6-well plates (Falcon) were infected with T7-recombinant vaccinia 
virus [strain vTF7.3 (101)] at a multiplicity of infection (MOI) of 20 and 1 hour later 
transfected with a maximum total of 3μg/well of plasmid DNA (1μg of each plasmid 
in cotransfections) using 5μl of Lipofectamine 2000 (Invitrogen)/well and following 
the manufacturer’s instructions. Transfected cells were harvested at 18 hours post-





transfected with 2μg of siRNAs in 1ml of serum free medium containing 5μl 
Transfectam reagent (Promega). After 6 hours at 37°C, cells were washed twice with 
serum free medium, incubated for additional 32-35 hours in medium supplemented 
with 10% foetal bovine serum (Invitrogen) and then infected with vaccinia virus and 
transfected as described above.  
For labelling with 35S-methionine, at 18 hours p.t. cells were starved with DMEM 
lacking methionine for 30min and were then labelled with 30μl (11.1MBq) of 35S-
methionine (ProMIX [35S] cell labelling mix, specific activity: >1000Ci 
(37,000GBq)mM-1, GE Healthcare). Subsequently, cells were washed with PBS and 
harvested. Labelled proteins were detected by autoradiography at -70°C using X ray 




Lysates (corresponding to about 5x105 cells) were prepared in 100μl of TNN lysis 
buffer (100mM Tris-HCl pH8.0, 250mM NaCl, 0.5%NP40) at 4°C and were 
subsequently centrifuged at 2000g for 5 minutes at 4°C. Usually 10μl of 
supernatants were used in PAGE and Western immunoblot analyses, and 40-80μl 
were used for immunoprecipitation experiments. The pellets were washed 3 times 
with PBS (170mM NaCl, 10mM phosphate, 3mM KCl, pH 7.4) and resuspended 
in 20μl of loading buffer for PAGE and Western blot analyses. 
 
CHEMICAL DSP CROSS-LINKING AND UV TREATMENT OF CELLS 
Dithiobis(succinimidylpropionate) (DSP) was purchased from Pierce. Monolayers of 





600μM DSP and incubated at 4°C for 30 minutes. After removing the reactant 
solution, the reaction was quenched twice with 2ml Tris Buffered Saline (TBS; 40mM 
TrisHCl pH8, 150mM NaCl) for 3 minutes at 4°C. Cellular extracts were prepared 
in 100μl TNN buffer as described above. 
For UV treatment, cells were washed twice with PBS and overlaid with 1ml TBS, kept 
on ice and exposed for 3 minutes  to 486mJ of UV light of 254nm wavelenght by UV 
Stratalinker 1800 (Stratagene). Cellular extracts were then prepared as described 
above.  
 
IMMUNOPRECIPITATION, PAGE AND WESTERN IMMUNOBLOT ANALYSIS  
Cellular extracts (usually 4/5 of the total extract, i.e. approx. 80μl) were 
immunoprecipitated for 2 hours at 4°C after addition of 1μl of undiluted antibody, 
1μl of 100mM PMSF, 50μl of 50% protein A-Sepharose CL-4B beads (Amersham 
Biosciences) in TNN buffer, and 20μl of TNN buffer. Beads were then washed four 
times with TNN buffer, once with PBS and resuspended in 20μl of loading buffer. 
Sample components were separated by SDS-PAGE (154) (using the Precision Plus 
Protein Standards molecular markers, Bio-Rad) and after electrophoresis transferred to 
polyvinylidene difluoride membranes (Millipore) (282). The membranes were 
incubated with the antibodies listed in Table 3. Signals were detected by using the 








RNase TREATMENT OF PROTEIN COMPLEXES 
For RNase treatment, cellular extracts were prepared by applying a lysis buffer 
consisting of PBS diluted 1:10 (to reduce salt concentration) and containing NP40 
(0.5%). Subsequently, 70μl of these extracts were treated with 10 units of RNase 
One (Promega) in 8μl of reaction buffer (provided by Promega) for 10 minutes at 
37°C. Afterwards, 1μl undiluted antibody, 50μl of 50% protein A-Sepharose CL-4B 
beads in TNN buffer, 1μl of 100mM phenylmethylsulfonyl fluoride (PMSF) and TNN 
buffer were added to obtain a final volume of 500μl for immunoprecipitation. 






λ-PHOSPHATASE TREATMENT OF IMMUNOPRECIPITATES 
70μl out of 100μl of a cellular extract obtained from transfection/infection of about 
5x105 cells were immunoprecipitated over night with anti-NSP5 serum and then 
divided in two aliquots to be incubated with or without 2μl of λ-phosphatase 
(400U/μl, BioLabs) in buffer for λ-phosphatase treatment (50mM Tris-HCl pH 7.5, 
100mM NaCl, 0.1mM EGTA, 2mM DTT, 0.01% Brij 35) (BioLabs) supplemented 
by 2mM MnCl2. The reaction was incubated for 2 hours at 30°C and was stopped 
with 10μl of PAGE loading buffer (40% glycerol, 6% SDS, 125mM Tris-HCl pH 6.8, 
0.04% bromo phenol blue, 5% β-mercaptoethanol). 
 
INDIRECT IMMUNOFLUORESCENCE MICROSCOPY 
For indirect immunofluorescence microscopy, cells were fixed in 3,7% 
paraformaldehyde in PBS for 10 minutes at room temperature. Cover slips were 
washed in PBS and blocked with 1% BSA in PBS for 30 minutes and incubated with 
primary antibody at room temperature. After three washing in PBS, slides were 
incubated either with another primary antibody for double staining or directly for 45 
minutes with RITC- or FITC-conjugated secondary antibodies. After three washings, 
nuclei were stained with Hoechst dye 2μg/ml for 10 min, washed and mounted with 
ProLong mounting medium (Molecular Probes). Samples were analysed by confocal 
microscopy (Axiovert; Carl Zeiss). The antibodies used in immunofluorescence are 









PURIFICATION OF VIRAL PARTICLES OBTAINED FROM CELLS EXPRESSING SV5-
TAGGED VP1 
Confluent monolayers of MA104 cells in six 6-well plates were infected with T7-
recombinant vaccinia virus (strain vTF7.3) at a MOI of 20 and 1 hour later 
transfected with pcDNA3-SV5-VP1 (2μg of DNA per well), using Lipofectamine 2000 
(Invitrogen, 5μl per well). Six hours p.t. cells were washed with serum free medium 
and infected with the bovine RF rotavirus strain at a MOI of 3. Viral particles were 
purified from cell cultures after harvest at about 20 hours p.i. when almost complete 






CPE had been reached. Virus was pelleted by ultracentrifugation, the pellets 
extracted with Freon (trichloro-trifluoro-ethane, Sigma) and banded by equilibrium 
ultracentrifugation in CsCl gradient, essentially as described by Patton et al. (205). 
This allowed to obtain three well separated gradient bands containing empty 
particles (EPs), TLPs and DLPs. Empty particle, TLP and DLP suspensions were diluted in 
20mM PIPES buffer pH6.6 containing 10mM CaCl2 and pelleted by 
ultracentrifugation at 110,000g for 1 hour in a Beckman ultracentrifuge using an 
SW55 rotor. The pellets containing the different viral particles were resuspended in 
35μl of water and used in SDS-PAGE and Western immunoblot analyses.  
 
EDTA TREATMENT OF PURIFIED TLPs  
Pellets derived from ultracentrifugation of CsCl purified TLP suspensions were 
resuspended in 60μl of PIPES buffer pH6.6 containing 0.5mM CaCl2 and treated 
with 5mM EDTA in PBS for 30 minutes at 37°C in modification of the procedure by 
Estes et al. (95). The resulting particles were pelleted by ultracentrifugation and 





The molecular events that take place during rotavirus replication are not yet 
completely elucidated. In particular, the intermediate structures formed during the 
sequential phases of genome replication and packaging, and the role of the different 
viral proteins in this process are not entirely clear. Although the involvement of the 
nonstructural proteins NSP2 and NSP5 in the replicative cycle is unquestioned, since 
in their absence viroplasms are not formed, genome viral replication does not occur 
and no infectious progeny virus is made, their precise functions also remain to be 
clarified. So far, a crucial structural role for NSP5 in the assembly of viroplasms, most 
likely through its interaction with NSP2, has been proposed. The data presented here 
suggest additional functions for NSP5 in the context of genome replication, being 
related to the interaction with the two structural proteins shown to be essentially 
involved in viral RNA replication: the polymerase VP1 and the scaffold protein VP2. 
In the first part [Results (1)], a characterization of the interaction between NSP5 and 
VP1 is presented and in the second part [Results (2)], a relevant effect of the scaffold 
protein VP2 on NSP5 cellular distribution and its hyperphosphorylation is described. 
In both parts of the Results section, the involvement of other viral proteins is examined 
with the aim to elucidate the temporal and spatial organization of the events leading 







VP1 coimmunoprecipitates with NSP5 
Previous experiments of our laboratory showed that a complex containing VP1, NSP2 
and NSP5 was immunoprecipitated by anti-NSP5 antibody from extracts of rotavirus-
infected cells, as long as cells were cross-linked in vivo with DSP (2). DSP is a 
reagent with two reactive groups separated by a spacer of 12Å length, able to 
permeate cell membranes and to cross-link proteins interacting inside the cell through 
their amino groups. In addition, a disulfide bridge within this spacer allows the 
separation of the components of the cross-linked complex under reducing conditions. 
Since VP1 was not coimmunoprecipitated by anti-NSP5 antibody without DSP cross-
linking and, differently from NSP2, not even after UV treatment (2), and based on the 
evidence of an interaction between NSP2 and VP1 (145), we were initially 
considering that an interaction between NSP2 and VP1 may be stronger than 
between NSP5 and VP1. With the aim of investigating the requirement of either of 
the two nonstructural proteins, and in particular of NSP5, in the interaction with VP1, 
we carried out experiments of transient expression of the single proteins. First, we 
found an interaction between NSP5 and VP1 in the absence of other viral proteins by 
coimmunoprecipitation with anti-NSP5 antibody from extracts of cells transiently 
transfected, labelled with 35S-methionine and in vivo cross-linked with DSP (Fig. 1A, 
lane 3). Coimmunoprecipitation of NSP2 with NSP5, which are well known to 
interact (2), served as an internal control (Fig. 1A, lane 2). A similar result was 
obtained with MA104 cells transfected with plasmids expressing the NSP5 and VP1 
genes, immunoprecipitated with anti-NSP5 antibody, and tested by Western blot with 





coexpressed with other viral proteins rather than alone (compare lanes 2-3 with lane 
1 of Fig.1A) was observed in several independent experiments (see also Figs. 9B, 
12, 27), although not in all of them (see Figs. 19A, 22A, 26, 28). This effect was 
shown to be non-specific by cotransfection of an irrelevant gene (EGFP) with genes 
expressing VP1 or VP2 in the presence of an internal control of transfection: since the 
levels of EGFP expression were lower than in the control of EGFP expressed alone 
(data not shown), it is probable that the plasmids or the mRNAs encoding VP1 and 
VP2 are favoured compared to those encoding NSP5 or EGFP in the competition for 
transcripition or translation factors. 
 
FIG. 1: Coimmunoprecipitation of VP1 and NSP5. A) Immunoprecipitation (ip) with anti-NSP5 serum 
of DSP cross-linked extracts of 35S-methionine labelled cells transiently transfected with the indicated 
genes. B) Western blot analysis of DSP cross-linked cellular extracts (lanes 1-4) and immunoprecipitates 
(lanes 5-8) derived from cells cotransfected with VP1 and NSP5. After separation by PAGE and 
Western blotting, the upper and lower parts of the blot were reacted with specific anti-VP1 and anti-
NSP5 antibodies, respectively. 
 
In order to further investigate the interaction between NSP5 and VP1, and because 
the anti-VP1 antibody did not react in immunoprecipitations nor in 
immunofluorescence, we used a VP1 derivative (tag-VP1) containing at its N-terminus 
the 12 amino acid long SV5 tag derived from a small epitope present on the P and V 





tag) was available. The amino acid sequence of this tag and a scheme of the gene 
encoding tag-VP1 are indicated in Fig. 2A. Extracts from cells cotransfected with 
NSP5 and tag-VP1 vectors (pT7v-NSP5 and pcDNA3-SV5VP1, respectively) were 
immunoprecipitated with either anti-NSP5 or the anti-tag antibody, and the 
immunoprecipitates were analyzed by Western blot with both antibodies. It was 
found that NSP5 and tag-VP1 coimmunoprecipitated in both cases (Fig. 2B). The 
ratio between the two proteins observed in the cellular extracts (Fig. 2B, lane 1) was 
found to be conserved in both coimmunoprecipitation approaches (Fig. 2B, lanes 6, 
10), suggesting a strong interaction between the two proteins. The comparison 
between assays using cross-linked or non-cross-linked cellular extracts revealed that 
DSP cross-linking was needed only for immunoprecipitations with anti-NSP5 antibody 
(Fig. 2C, compare lanes 3 and 6), but not with the anti-tag antibody (Fig. 2C, 
compare lanes 9 and 12), suggesting that the high-affinity hyperimmune polyclonal 
anti-NSP5 antibody might have dissociating activity. To test whether cellular RNA 
mediates interaction between NSP5 and VP1, cellular extracts from non-cross-linked 
cells were treated or not treated with the ribonuclease RNase One before 
immunoprecipitation and Western blot analysis. This ribonuclease has been chosen, 
because it cleaves the phosphodiester bond between any two ribonucleotides and 
allows the degradation of both single-strand and double-strand RNA. Since this 
ribonuclease is inhibited by high concentrations of sodium chloride and potassium 
phosphate, cellular extracts were prepared by applying a lysis buffer consisting of 
PBS diluted 1:10 (to reduce salt concentration) and containing NP40 (0.5%). Figure 
2D shows that RNase treatment did not change the ability of anti-tag antibody to 
coimmunoprecipitate NSP5, indicating that cellular RNA does not mediate interaction 








FIG. 2: Coimmunoprecipitation of NSP5 and tagged VP1. A) Amino acid sequence of SV5 tag, 
indicated in colour purple, and diagram of tag-VP1 gene. B) Western blot of immunoprecipitates of 
DSP cross-linked extracts from MA104 cells cotransfected with NSP5 and tag-VP1 genes. 
Immunoprecipitates were obtained with an anti-NSP5 serum (anti-NSP5) or the anti-SV5 monoclonal 
antibody (anti-tag) and upper and lower parts of the blots developed with either of them, as indicated. 
C) Western blot of immunoprecipitates obtained with anti-NSP5 or anti-tag from extracts of both non-
cross-linked or DSP cross-linked cells, and developed with the indicated antibodies. D) Western blot of 
immunoprecipitates obtained with anti-tag antibody from extracts of non-DSP cross-linked cells, treated 





We also examined UV treatment of cells as an alternative method to cross-link nucleic 
acids to proteins. It has been previously observed that UV treatment of rotavirus-
infected cells allowed stabilization of NSP5-NSP2 complexes, which could be 
immunoprecipitated by anti-NSP5 antibodies. Under these conditions, 
coimmunoprecipitation of VP1 did not take place and required cross-linking with DSP 
(2). In agreement with this finding and with the lack of an effect of RNase digestion, 
UV treatment of cells coexpressing tag-VP1 and NSP5 did not result in 
coimmunoprecipitation of tag-VP1 with anti-NSP5 antibody (Fig. 3). 
 
 
FIG. 3: Western blot of immunoprecipitates of extracts from MA104 cells cotransfected with NSP5 
and tag-VP1 and exposed to UV treatment. Immunoprecipitates were obtained with anti-NSP5 or anti-
tag antibodies and upper and lower parts of the blots developed with either of them, as indicated.  
 
Tag-VP1 can act as a structural replacement of VP1 
To ensure the validity of using tag-VP1 instead of VP1, the behaviour of the tagged 
protein in the course of viral infection was investigated. We tested whether the 
transfected tag-VP1 was incorporated into particles of viral progeny in MA104 cells 
expressing tag-VP1 and infected with rotavirus. To allow this, cells were first infected 
with vTF7.3 recombinant vaccinia virus, which increases the expression level of 
proteins encoded by genes positioned under the control of the T7 promoter. One 





superinfected with the rotavirus RF strain. Twenty hours after rotavirus infection, viral 
progeny particles were concentrated by sedimentation and purified by CsCl gradient 
ultracentrifugation. Fractions of gradients containing the visible bands of empty 
particles (EPs; density 1.30g/ml), TLPs (1.36g/ml) and DLPs (1.38g/ml) (92) were 
analyzed by Western blot with anti-tag and anti-VP1 antibodies. Since VP7 is present 
only in TLPs, Western blot analysis with anti-VP7 antibodies was also performed as a 
control. Cellular extracts of transfected cells in the presence or in the absence of 
vaccinia virus and/or rotavirus were tested in the same way. The whole procedure is 
illustrated in the scheme of Fig. 4A. Tag-VP1 was found to be incorporated into viral 
particles in a reproducible fashion in several experiments (Fig. 4). These experiments 
showed some variability in the relative amounts of tag-VP1 found in TLPs, DLPs and 
EPs. In some experiments tag-VP1 was incorporated mostly into TLPs, and only faint 
tag-VP1 bands were observed in DLPs and EPs (Fig. 4B); in others, tag-VP1 was 
preferentially present in DLPs (Fig. 4D). To rule out non-specific trapping of tag-VP1 in 
the outer shell of TLPs, we treated purified TLPs with EDTA to remove the outer layer 
(95). The treatment did not release tag-VP1 (Fig. 4D), indicating that tag-VP1 was 
genuinely incorporated into DLPs. This conclusion was strengthened by comparison of 
the relative amounts of VP1 (anti-VP1) and tag-VP1 (anti-tag) in lanes 10, 13 and 14, 
which showed similar ratios. The difference in PAGE mobility between tag-VP1 and 
wild-type VP1 (Fig. 4C) was due to the two different parental strains (tag-VP1, SA11 






             
 
 
FIG. 4: Packaging of tag-VP1. A) Scheme of the technical procedure. B) Rotavirus particles (T=TLPs; 
D=DLPs; E=EPs) obtained from cells transfected with tag-VP1 (lanes 1-3) or non-transfected (lanes 4-6) 
were analyzed by Western blot as indicated. C) Western blot of total cellular extracts. Lane 9 
corresponds to the conditions under which viral particles shown in lanes 1-3 were obtained. Of note, 
tag-VP1 (SA11 strain, lane 8) migrated faster than the untagged VP1 (RF strain, lane 7). D) Western 
blot with anti-tag, anti-VP1 and anti-VP7 antibodies of TLPs, DLPs and EPs (lane 10-12, respectively). 
Tag-VP1 TLPs and control TLPs were treated with EDTA as described (T+E, lanes 13 and 15, 
respectively) or mock-treated (lanes 14 and 16, respectively). Traces of VP7 in the DLP preparations 






Tag-VP1 colocalizes with NSP5 in viroplasms and in VLS 
In virus-infected cells, NSP5 and VP1, as well as NSP2, colocalize in the cytoplasmic 
viroplasms. In addition, we found that tag-VP1 also localizes in viroplasms. As shown 
in Fig. 5, confocal microscopy with different fluorescence labels for the NSP5 and 
the tag-VP1 signals revealed that part of tag-VP1 colocalized with NSP5 in the 
viroplasms of rotavirus-infected cells. When tag-VP1 was coexpressed in uninfected 
cells, either with NSP5 or with NSP2 in the absence of any other rotavirus protein, a 
diffuse cytoplasmic distribution for each individual protein was observed (Fig. 6A, 
horizontal rows 2 to 3). By contrast, when NSP5 and NSP2 were both present, a 
substantial part of tag-VP1 was found to localize in the characteristic viroplasm-like 
structures (VLS), which are formed by the two nonstructural proteins (96) (Fig. 6A, row 
4, and Fig. 6B). This was further confirmed by cotransfecting NSP2 with a mutant of 
NSP5 lacking the 18 amino acid C-terminal tail region (ΔT), which had previously 
been demonstrated to be unable to form VLS (96). As expected, all three proteins 
showed a diffuse distribution (Fig. 6A, row 5). While VLS of cells containing tag-VP1 
appear to be smaller and less numerous than VLS formed only by NSP5 and NSP2, 
they still retain the typical ring appearance (Fig. 6A, row 4). 
 
 
FIG. 5: Colocalization of tag-VP1 in viroplasms. 
Confocal immunofluorescence of tag-VP1 (green) 
and NSP5 (red) in MA104 cells, transfected 
with the tag-VP1 expressing plasmid and 
infected with SA-11 rotavirus. The individual and 






FIG. 6: Localization of tag-VP1 in viroplasm-like structures (VLS). A) Immunofluorescence of tag-VP1 
(green), NSP2 (red) and NSP5 (red) in cells cotransfected with the indicated genes. B) Colocalization 
of tag-VP1 and NSP5 in VLS formed in cells coexpressing NSP5, NSP2 and tag-VP1, as shown by 





VP1 interacts more strongly with NSP5 than with NSP2  
As previously mentioned, NSP5, NSP2 and VP1 can be coimmunoprecipitated from 
virus-infected cells (1). Similarly, all three proteins were coimmunoprecipitated by anti-
NSP5 antibody from DSP cross-linked extracts of cells coexpressing them in the 
absence of other viral proteins (Fig. 7A, lane 6). As previously reported, anti-NSP2 
antibody did not pull down NSP5 (2) nor tag-VP1 (data not shown). 
We investigated the ability of VP1 to interact with either of the two nonstructural 
proteins by comparing the ability of anti-tag antibody to coimmunoprecipitate NSP5 
and/or NSP2 from extracts of DSP cross-linked and, more importantly, non-cross-
linked cells. Anti-tag antibody was able to coimmunoprecipitate NSP5 and NSP2 
when tag-VP1 was coexpressed with either of them (Fig. 7B, lanes 7, 8 and 10, 11) 
or with both (Fig. 7B, lanes 9, 12). However, coimmunoprecipitation of NSP5 is 
much more efficient than coimmunoprecipitation of NSP2. In fact, although the input 
of cellular extracts used for immunoprecipitations represented four times as much as 
used for the analysis of cellular extracts (Fig. 7B, lanes 1 to 6), only a small fraction 
of NSP2 was recovered from the immunoprecipitates (about one fifth to one tenth: 
compare lanes 8, 9, 11, 12 with lanes 2, 3, 5, 6 of Fig. 7B), whereas the amount 
of NSP5 recovered was significantly larger (about five to ten times: compare lanes 7, 
9, 10, 12 with lanes 1, 3, 4, 6 of Fig. 7B). In several experiments we observed that 
the amount of NSP2 coimmunoprecipitated from DSP cross-linked extracts with VP1 
was larger when NSP5 was present (Fig. 7B, compare lanes 11 and 12). Altogether 
these data indicate that in the presence of NSP2 the interaction of VP1 with NSP5 is 







FIG. 7: Coimmunoprecipitation of NSP2, NSP5 and tag-VP1. A) Western blot of cellular extracts 
(lanes 1-3) or anti-NSP5 immunoprecipitates (lanes 4-6) derived from cells transfected with NSP2, 
NSP5 and tag-VP1 and DSP cross-linked. B) Western blot of cellular extracts (lanes 1-6) or anti-tag 
immunoprecipitates (lanes 7-12) derived from cells transfected with NSP2, NSP5 and tag-VP1, DSP 
cross-linked (lanes 4-6, 10-12) or non-cross-linked (lanes 1-3, 7-9). Upper, middle and lower parts of 
the blots were cut and reacted with anti-tag, anti-NSP2 and anti-NSP5 antibodies, respectively. 
 
Since NSP5 becomes hyperphosphorylated in the presence of NSP2 (2), we 
expected to find the hyperphosphorylated forms of NSP5 in the immunoprecipitates. 
However, after DSP cross-linking, these forms were only found in the insoluble 
fraction, which contains approximately 50% of the total amount of NSP5 (Fig. 8A, 
lane 4), and were surprisingly absent when tag-VP1 and NSP2 were present (Fig. 
8A, lane 6). Furthermore, even in extracts not cross-linked with DSP, the relative 
hyperphosphorylation of NSP5 in cells coexpressing tag-VP1 and NSP2 was clearly 
impaired. In fact, the ratio between bands at 28 and 26KDa was about 1:10 (Fig. 
8B, lane 3), like for NSP5 expressed alone, while it is about 1:1 to 1:2 when NSP5 
is expressed with NSP2 only (Fig. 8B, lane 1). This suggests that VP1 somehow 







FIG. 8: Effect of DSP cross-linking and tag-VP1 on NSP5 hyperphosphorylation. A) Western blot 
analysis of soluble (left panel, lanes 1-3) and insoluble (right panel, lanes 4-6) fractions derived from 
extracts of DSP cross-linked cells transfected with the indicated genes. B) Western blot of the soluble 
fractions of non-cross-linked cells. Upper, middle and lower parts of the blots were cut and reacted 
with anti-tag, anti-NSP2 and anti-NSP5 antibodies, respectively. 
 
The C-terminal 48 amino acids of NSP5 are essential for interaction with VP1 
To map the region of NSP5 essential for the interaction with VP1, we first performed 
coimmunoprecipitation assays using DSP cross-linked extracts of cells cotransfected 
with plasmids encoding tag-VP1 and the deletion mutants of NSP5 illustrated in Fig. 
9A. Only traces of mutants Δ2 and Δ4 (lacking amino acids 34-80 and 131-179, 
respectively) were detectable in both the extracts and the anti-NSP5 
immunoprecipitates in several experiments (Fig. 9B, lanes 5, 7, 13, 15, 21, 23). 
However, tag-VP1 was surprisingly coimmunoprecipitated with all NSP5 mutants 
using anti-NSP5 antibodies, and consistently, all NSP5 mutants were 
coimmunoprecipitated by anti-tag antibody (Fig. 9B, lanes 11-16, 20-24) (with the 
exception of Δ4, whose expression was compromised for unknown reasons, as 
shown in Fig. 9B, lane 23). The comparison of the ratios between tag-VP1 and the 





revealed a good interaction between tag-VP1 and Δ1 (lacking the first 33 N-terminal 
amino acids) (Fig. 9B, lanes 4, 12, 20) and a weak interaction between NSP5 and 
ΔT (lacking the 18 amino acid long C-terminal tail). In fact, lane 16 of Fig. 9B shows 
a small fraction of NSP5 coimmunoprecipitated from the total amount present in the 
extract (visualized in lane 8) and, consistently, lane 24 shows a small fraction of 
coimmunoprecipitated tag-VP1. Therefore, we proceeded with coimmunoprecipitation 
assays of DSP cross-linked extracts of cells cotransfected with wild-type VP1 and Δ1 
or wild-type VP1 and ΔT. As confirmed in Fig. 9C, anti-NSP5 coimmunoprecipitated 
VP1 when coexpressed with Δ1, whereas only a small amount of VP1 was obtained 
when VP1 was coexpressed with ΔT. In conclusion, these data indicate that the 
interaction with VP1 did not involve the N-terminal region of NSP5 and was 











FIG. 9: Interaction of VP1 with NSP5 mutants. A) Diagram of NSP5 mutant constructs used. B) 
Western blots of DSP cross-linked cellular extracts and immunoprecipitates of cells cotransfected with 
tag-VP1 and NSP5 or NSP5 mutants, as indicated. C) Western blots of DSP cross-linked cellular 










For further confirmation, we used other constructs, in which enhanced green 
fluorescent protein (EGFP) was fused to different regions of NSP5 (see diagrams in 
Fig. 10A). Cells were cotransfected with tag-VP1 and the different EGFP constructs 
and DSP cross-linked, and lysates were immunoprecipitated with anti-tag antibody. 
While the EGFP protein fused with only region 1 was not coimmunoprecipitated with 
anti-tag antibody, the fusion proteins containing regions 4 and T (amino acids 130 to 
198), with or without region 1, were pulled down (Fig. 10B), confirming that the N-
terminus does not bind to VP1 and, more importantly, that the last 68 amino acids 
(4T) were sufficient for the interaction. Furthermore, coimmunoprecipitation of tag-VP1 









FIG. 10: Interaction of VP1 with NSP5 mutants. A) Diagram of NSP5 constructs used. B) Western blots 
of cellular extracts and immunoprecipitates of DSP cross-linked cells cotransfected with tag-VP1 and 
different NSP5-EGFP fusion constructs, as indicated. 
 
 
In order to better define the region involved in the interaction with VP1, we analyzed 
another deletion mutant of NSP5, lacking the last 48 amino acids (ΔC48) (see 
diagram in Fig. 11A). In parallel, we tested mutants ΔT and Δ4ΔT as controls. After 
cotransfection with tag-VP1, the anti-tag antibody did not coimmunoprecipitate 
ΔC48, nor did anti-NSP5 tag-VP1 (Fig. 11B). Moreover, when supernatants of 
samples already immunoprecipitated with anti-tag were subsequently 
immunoprecipitated with anti-NSP5, the non-interacting mutants (ΔT, Δ4ΔT and 







To rule out the possibility that the lack of interaction of mutant ΔC48 with tag-VP1 
was the consequence of the removal of a series of basic residues (two arginines and 
seven lysines, see Fig. 11A) that could have been involved in the cross-linking with 
DSP, we carried out immunoprecipitations with anti-tag, which does not require cross-
linking and efficiently coimmunoprecipitates wild-type NSP5. As shown in Fig. 11D, 
anti-tag was completely unable to coimmunoprecipitate ΔC48. Taken together, the 
results presented in figures 9 to 11 indicate that the 48 amino acids of the C-terminal 









FIG. 11: Interaction of VP1 with NSP5 mutants. A) Diagram of ΔC48 mutant in comparison with wt 
NSP5 and amino acid sequence of the region deleted in ΔC48. B) Western blots of cellular extracts 
and immunoprecipitates of cells cotransfected with tag-VP1 and NSP5 deletion mutants, and DSP 
cross-linked, as indicated. C) Western blots of supernatants (sn) derived from anti-tag 
immunoprecipitates of Fig. B and immunoprecipitated with anti-NSP5. D) Western blot of extracts and 
immunoprecipitates derived from cells cotransfected with tag-VP1 and either wt NSP5 or ΔC48 









The VP1 C-terminal 15 amino acids seem to be involved in interaction with NSP5 
The following experiment was based on a personal communication by Dr. John 
Patton (National Institute of Allergy and Infectious Diseases, NIH), who has 
crystallized and determined the structure of VP1 (not yet published). They found that 
the fifteen C-terminal residues of VP1 form an α-helical plug, which reduces for almost 
half the diameter of the (-)ssRNA/dsRNA exit channel. We hypothesized an 
interaction between this region of VP1 with NSP5, which might move the plug 
affecting production of (-)ssRNA/dsRNA. We constructed a tagged deletion mutant 
of VP1 lacking the last fifteen amino acids (tag-VP1ΔC15). Preliminary data of 
coimmunoprecipitation of NSP5 with tag-VP1ΔC15 suggest the involvement of the 
VP1 C-terminus in the interaction with NSP5. Extracts of cells coexpressing NSP5 and 
either wild-type VP1 or tag-VP1ΔC15, treated or not treated with DSP, were 
immunoprecipitated with anti-NSP5 and anti-tag antibodies, respectively. Analysis of 
the immunoprecipitates showed that NSP5 was not coimmunoprecipitated with tag-
VP1ΔC15 by anti-tag antibody from non-DSP cross-linked extracts, while it was with 
wild-type tag-VP1 (Fig. 12, compare lanes 3, 8 and lanes 5, 10). On the other 
hand, very small amounts of tag-VP1ΔC15 were coimmunoprecipitated with NSP5 
by anti-NSP5 antibodies from DSP cross-linked extracts (Fig. 12, compare lanes 13, 
18 and lanes 15, 20). Taken together, these preliminary data suggest an 






FIG. 12: Interaction of NSP5 with tag-VP1ΔC15. Western blot analysis of DSP cross-linked or non-
cross-linked extracts of cells cotransfected with NSP5 and tag-VP1 or tag-VP1ΔC15, and of the 








Like VP1, the scaffold protein of the core, VP2, has been shown to be critically 
involved in viral RNA replication and to localize in viroplasms. Furthermore, an 
interaction with NSP5 has been described (23), although in our laboratory we never 
succeeded in coimmunoprecipitating VP2 with NSP5 from rotavirus-infected cells, 
even after cross-linking with DSP. In the following Results (2) section, we investigated 
the behaviour of VP2 after coexpression with NSP5 in uninfected cells. Furthermore 
(as we have done when investigating the interaction between VP1 and NSP5), we 
coexpressed other viroplasmic proteins together with VP2 and NSP5 and tested their 
interactions by confocal immunofluorescence and coimmunoprecipitation experiments. 
Studying the interactions and the relative localization of the single viroplasmic 
components is aimed at understanding the still undefined process of viroplasm 
assembly, which is critical for viral RNA replication and packaging as well as for 
viral particle formation. 
 
VP2 induces NSP5 to form VLS 
Following coexpression of NSP5 and VP2 in uninfected cells, immunofluorescence 
experiments with anti-NSP5 antibodies revealed the formation of structures similar to 
those formed by NSP5 and NSP2, but less numerous and less uniformly distributed 
(Fig. 13). Based on the morphological similarity with VLS formed by NSP5 and 
NSP2, we named these structures VLS as well and in order to distinguish between 
VLS induced by NSP2 from those induced by VP2, we named them VLS(NSP2i) and 






FIG. 13: VLS(VP2i). Immunofluorescence of NSP5 and VP2 in cells cotransfected with 1μg of both 
NSP5 and VP2 plasmids or with either of them, as indicated. 
 
By immunofluorescence with anti-VP2 antibodies, a diffuse distribution of VP2 was 
frequently observed when 1μg of both plasmids was transfected (Fig. 13). However, 
a clear recruitment of VP2 into VLS(VP2i) was easily detectable, when the amount of 
the plasmid encoding VP2 was reduced to 0.1μg or 0.01μg (Fig. 14).  
 
FIG. 14: VP2 recruitment into VLS(VP2i). Immunofluorescence of VP2 in cells cotransfected with 





Recruitment of VP2 into VLS(VP2i) was further confirmed using a stable cell line 
expressing the fusion protein NSP5-EGFP. The fluorescence of NSP5-EGFP in these 
cells can be visualized, when the fusion protein is concentrated in viroplasms 
following rotavirus infection (Fig. 15). Transfection of VP2 plasmid in this cell line led 
to the formation of visible VLS(VP2i). This was observed either by the autofluorescence 
of NSP5-EGFP or by immunofluorescence with anti-NSP5 antibodies (Fig. 16A). VP2 
was found colocalized with NSP5-EGFP in these structures as long as the plasmid 
encoding wild-type NSP5 was also cotransfected (compare bottom row of Fig. 16A 
with Fig. 16B). The need of wild-type NSP5 was observed even when NSP2 plasmid 
was transfected in this cell line, with the interesting difference that the wild-type NSP5 
coexpression was required not only for the recruitment of NSP2 into VLS, but also for 
VLS(NSP2i) formation (Fig. 16C,D). 
 
 








FIG. 16: VLS formation in transfected MA104 NSP5-EGFP stable cell line. A-B) Fluorescence of NSP5-
EGFP (green) and immunofluorescence of NSP5 or VP2 (red) in MA104 NSP5-EGFP cells transiently 
transfected with VP2 (A) or cotransfected with VP2 and NSP5 plasmids (B). C-D) Fluorescence of 
NSP5-EGFP (green) and immunofluorescence of NSP5 or NSP2 (red) in MA104 NSP5-EGFP cells 





Cotransfection of the NSP5-EGFP cell line with both VLS-inducers VP2 and NSP2 led 
to the formation of VLS, where neither VP2 nor NSP2 were recruited, and with the 
typical distribution of VLS(VP2i) (Fig. 17A). However, when wild-type NSP5 was also 
cotransfected, VLS containing all three components were observed in numbers and 





                 
   
FIG. 17: VLS formation in transfected MA104 NSP5-EGFP stable cell line. Fluorescence of NSP5-
EGFP (green) and immunofluorescence of VP2 (red), NSP2 (red) or NSP5 (red) in MA104 NSP5-EGFP 
cells transiently cotransfected with VP2 and NSP2 plasmids with (B) or without (A) concomitant 





The need of wild-type NSP5 could be explained either by an inadequate ratio 
between VP2 or NSP2 and NSP5-EGFP in the stable cell line or by the requirement 
of a free C-terminus in at least a fraction of NSP5 molecules. In order to discriminate 
between these two interpretations, wild-type MA104 cells were transiently 
cotransfected with 1μg of NSP5-EGFP plasmid and 0.1μg of VP2 plasmid. As shown 
in Fig. 18, VLS(VP2i) formed exclusively by NSP5-EGFP were able to recruit VP2, 
suggesting that the ratio between NSP5 and VP2 proteins was the critical variable 
affecting VLS formation. 
 
 
FIG. 18: VLS(VP2i) formation in wild-type MA104 cells transiently cotransfected with 1μg of NSP5-
EGFP plasmid and 0.1μg of VP2 plasmid, as indicated by fluorescence of NSP5-EGFP (green) and 
immunofluorescence of VP2 (red). 
 
All these data suggest that cotransfection of plasmids encoding viroplasmic proteins 
can be considered a valid strategy towards the understanding of the assembly of 
viroplasms. The data also show how critical the relative amounts of the different 
viroplasmic components are in determining the formation of these structures. 
 
VP2 increases NSP5 hyperphosphorylation 
Western blot experiments on extracts of uninfected cells cotransfected with VP2 and 





19A, lane 5). When NSP5 is expressed alone, one main band is visible at 26KDa 
and a much weaker band of phosphorylated NSP5 at 28KDa (Fig. 19A, lane 4). By 
contrast, in extracts of infected cells the band at 28KDa is much more abundant and 
a series of higher bands is visible, whose apparent molecular weights span from 30 
to 34KDa (Fig. 19A, lane 2). As mentioned in the Introduction, all bands different 
from 26KDa have previously been shown to correspond to many different 
phosphorylated isoforms of NSP5 (3, 26, 112, 228). We found that the pattern of 
bands of NSP5 coexpressed with VP2 in uninfected cells was similar although not 
identical to that observed for NSP5 from infected cells (compare lanes 2 and 5 of 
Fig. 19A). We verified that the effect of VP2 on NSP5 was actually an increased 
hyperphosphorylation by treatment with lambda-phosphatase. Following 
immunoprecipitation with anti-NSP5 antibodies of NSP5 coexpressed with VP2, 
immunoprecipitates treated with lambda-phosphatase showed a single band at 
26KDa (Fig. 19B, lanes 3, 4). In addition, we performed in vivo experiments 
coexpressing NSP5, VP2 and the catalytic subunit of the cellular phosphatase PP2A, 
which is an ubiquitous and conserved serine/threonine phosphatase with broad 
substrate specificity (298). As shown in Fig. 19C, the presence of the catalytic 
subunit of PP2A led to a significant reduction of the NSP5 bands at higher molecular 
weight and to an inversion of the relative intensity of the bands at 26KDa and 
28KDa (Fig. 19C, lanes 3, 6). All these data confirm that the presence of VP2 
increases NSP5 hyperphosphorylation. The mechanisms and the enzymes involved in 
this process remain obscure. Attempts of coimmunoprecipitation of NSP5 and/or VP2 
with the catalytic and regulative subunits of PP2A were performed, but neither NSP5 
nor VP2 were found coimmunoprecipitated with PP2A (data not shown). Moreover, 
by experiments of RNA interference against kinase CK1α, which was recently shown 





CK1α does not contribute significantly to the effect of VP2. Lane 2 of figure 20 
shows a very slight conversion of the band at 28KDa to the band at 26KDa and the 
pattern of all bands resembles that of NSP5 coexpressed with VP2 and an irrelevant 
siRNA (even though the absolute amount of NSP5 is lower and the intensity of all 
bands is reduced) (compare lane 1 and 2). Beyond questioning the involvement of 
this kinase in the VP2-mediated NSP5 hyperphosphorylation, these data suggest that 
the concurrence of different kinases and phosphatases takes place in the context of 






FIG. 19: NSP5 hyperphosphorylation induced by VP2. A) Western blot analysis of extracts of 
rotavirus-infected MA104 cells and cells cotransfected with NSP5 and VP2 plasmids. B) Western blot 
of immunoprecipitates, treated or mock-treated with lambda-phosphatase, from extracts of cells 
cotransfected with the indicated genes. C) Western blot analysis of extracts of cells coexpressing the 









VLS formation and VP2-induced NSP5 hyperphosphorylation 
Since VP2 induces both VLS formation and NSP5 hyperphosphorylation, we 
investigated whether there was a correlation between the two events. By 
immunofluorescence, we tested the formation of VLS in four different conditions, in 
which inhibition of VP2-induced NSP5 hyperphosphorylation was observed: 
- coexpression of the catalytic subunit of phosphatase PP2A: although PP2A 
induces a decrease of NSP5 hyperphosphorylation induced by VP2 (Fig. 
19C), the formation of VLS(VP2i) was not impaired and the cytoplasmic 
distribution of VLS(VP2i) in these conditions was similar to that of VLS(NSP2i) 
(Fig. 21A, picture C and 21B, picture E). Interestingly, the pattern of bands of 
NSP5 coexpressed either with VP2 and PP2A or with NSP2 is very similar 
(compare lane 6 of Fig. 19C with lane 1 of Fig. 8B).  
FIG. 20: Involvement of kinase CK1α in NSP5 
hyperphosphorylation induced by VP2. Western blot of extracts 
of cells transiently cotransfected with NSP5 and VP2 plasmids 







FIG. 21: VLS formation in MA104 cells coexpressing NSP5, VP2 and the catalytic subunit of 
phosphatase PP2A. A) Single immunofluorescence of HA-PP2A (green), NSP5 (red) and VP2 (red) 
in cells cotransfected with the indicated genes. B) Confocal microscopy showing the relative 
localization in the same cell of NSP5 (red) and HA-PP2A (green) upon cotransfection with the 
indicated genes. 
 
- coexpression of tag-VP1: surprisingly, coexpression of tag-VP1 with VP2 and 
NSP5 in uninfected cells hampered the effect of VP2 on NSP5 
hyperphosphorylation (Fig. 22A, see also Fig. 27, lanes 4, 12), which is 
consistent with the evidence of an inhibitory activity of tag-VP1 on the NSP2-
mediated NSP5 hyperphosphorylation (Fig. 8B). It remains to be investigated 
whether this is due to a depletion of substrate by tag-VP1 because of its strong 
interaction with NSP5 or to other mechanisms. Apart from that, when NSP5 is 
coexpressed with tag-VP1 and VP2 and its hyperphosphorylation decreases, 
VLS(VP2i) are still formed (Fig. 22B) and, interestingly, tag-VP1 is recruited into 







          
 
 
FIG. 22: Coexpression of tag-VP1, VP2 and NSP5 in MA104 cells. A) Western blot analysis of 
extracts of cells cotransfected with the indicated combinations of tag-VP1, VP2 and NSP5 
plasmids. B) Colocalization of tag-VP1 and NSP5 or tag-VP1 and VP2 in VLS formed in cells 
coexpressing NSP5, VP2 and tag-VP1, as shown by confocal microscopy with anti-NSP5 (red) 
and anti-tag (green) or with anti-VP2 (red) and anti-tag (green) antibodies. 
 
- coexpression of NSP5 phosphorylation mutants: as explained in the 
Introduction, NSP5 phosphorylation has been described as a hierarchical 
process starting from phosphorylation of a serine residue in position 67 (87). 
We coexpressed VP2 with either a point mutant of NSP5 containing an 
alanine in position 67 (S67A) or a mutant called NSP5a, where serines in 
positions 63, 65 and 67 were all substituted with alanines, in order to 
remove all phosphorylation sites from the entire serine-rich motif (Fig. 23A). 
The effect of VP2 on hyperphosphorylation and cellular distribution of the 
NSP5 point mutants were analyzed by Western blotting and 
immunofluorescence. As shown in Fig. 23B, VP2 increases the 
hyperphosphorylation of both mutants only slightly and does not induce the 
inversion of the ratio 26/28KDa typically observed in wild-type NSP5 






suggests the involvement of additional phosphorylation sites on NSP5 
sequence. Importantly, despite being only slightly hyperphosphorylated in the 
presence of VP2, these mutants still form VLS, as shown by 
immunofluorescence in Fig. 23C. 







FIG. 23: Coexpression of VP2 with NSP5 phosphorylation mutants. A) Scheme of the mutated residues 
in NSP5 phosphorylation mutants. B) Western blot analysis of extracts of cells cotransfected with genes 
encoding VP2 and wild-type NSP5 or NSP5 phosphorylation mutants, as indicated. C) Localization of 
VP2 and wild-type NSP5 or NSP5 phosphorylation mutants in VLS formed in cotransfected MA104 








- coexpression of VP2 with low increase of NSP5 phosphorylation: when the 
relative amounts of plasmids encoding VP2 and NSP5 were varied, we found 
that a ratio corresponding to 1:10 (precisely 0.1μg pcDNA3-VP2 and 1μg 
pT7v-NSP5) does not lead to the typical increase of the band at 28KDa and 
the corresponding decrease of the band at 26KDa (Fig. 24A, lane 2). Under 
these conditions, most of NSP5 shows a pattern similar to NSP5 expressed 
alone, with the band at 26KDa mainly represented (Fig. 24A, lane 1). 




FIG. 24: Cotransfection of 1μg of NSP5 plasmid and 0.1μg of VP2 plasmid in MA104 cells. A) 
Western blot of extracts of MA104 cells cotransfected with different ratios between NSP5 and VP2 
plasmids, as indicated. B) Localization of NSP5 and VP2 in VLS(VP2i) in MA104 cells transiently 
cotransfected with 1μg pT7v-NSP5 and 0.1μg pcDNA3-VP2, as shown by single immunofluorescence 







In summary, in all four conditions examined, NSP5 hyperphosphorylation induced by 
VP2 was significantly reduced, and yet VLS formation was not altered. Therefore, it is 
reasonable to conclude that the strong VP2-mediated NSP5 hyperphosphorylation 
does not correlate with VLS formation. However, stating that the two processes are 
totally unrelated would be imprecise, because in all the examples reported inhibition 
of the effect of VP2 on NSP5 hyperphosphorylation was never complete, and it could 
be argued that the residual fully hyperphosphorylated molecules suffice to drive VLS 
formation. 
 
From VLS to viroplasms 
Despite viroplasms being well defined morphological entities in rotavirus-infected 
cells, their detailed assembly has not been elucidated yet. It is known that they 
contain structural (VP1, VP2, VP3, VP6) and nonstructural proteins (NSP5, NSP2), but 
the recruitment of these proteins and their activities inside viroplasms remain unknown. 
Based on the morphological similarity with viroplasms, VLS might represent 
“incomplete viroplasms” and we are trying to coexpress all viroplasmic proteins in 
different combinations in order to understand the mechanisms of viroplasm assembly. 
Furthermore, these efforts require also to take into consideration recruitment into VLS of 
“viral” RNAs.  
Until now, we have found that: 
- VP2 and NSP2 are both VLS-inducers [(96); Fig. 6A, row 1; Fig. 13] 
- VP1 is recruited into both VLS(NSP2i) and VLS(VP2i) (Fig. 6A, row 4; Fig. 
22B); 






Like VP1, when the middle layer protein VP6 is coexpressed with NSP5, it does 
not induce VLS formation (Fig. 25, upper row) and forms tubular structures, as it 
does when expressed alone (data not shown). However, following coexpression 
of VP6 with NSP5 and VP2, we observed total recruitment of VP6 into VLS(VP2i) 
(Fig. 25, middle row), while coexpression with only VP2 in the NSP5-EGFP cell 
line led to a much less evident recruitment, despite the fact that VLS(VP2i) were 
clearly visible and VP6 tubules absent (Fig. 25, compare middle row with bottom 
row). Again, as in the previous experiments, the results obtained so far probably 
depend on the relative amounts of the coexpressed proteins. 
 
 
FIG. 25: Recruitment of VP6 into VLS formed in MA104 NSP5-EGFP cells transiently transfected with 
the indicated genes, as shown by confocal microscopy with the fluorescence of NSP5-EGFP (green) 
and with anti-VP6 antibodies (red). 
 
The only viroplasmic protein, whose recruitment into VLS was not investigated, is VP3, 





In conclusion, the data we have so far collected suggest a crucial role for NSP5 as 
an organizer of viroplasms, because it is the only protein essential for the formation of 
VLS induced in different ways and able to recruit other viroplasm components (NSP2, 
VP2, VP1, VP6).  
Since all the immunofluorescence experiments indicated an association among the 
different viroplasmic proteins in structures similar to viroplasms, we attempted to verify 
these associations by coimmunoprecipitation experiments [as it has already been 
shown for NSP5, NSP2 and tag-VP1 in Results(1)]. First, we tried to 
coimmunoprecipitate VP2 and NSP5 from extracts of cells cotransfected with NSP5 
and VP2 genes, without success. While both NSP5 and VP2 were well expressed, 
VP2 was not coimmunoprecipitated from cellular extracts with anti-NSP5 (Fig. 26, 
lanes 13, 16), regardless of whether cells had previously been treated or not treated 
with DSP. Similarly, anti-VP2 antibodies did not coimmunoprecipitate NSP5 (Fig. 26, 
lane 20). In addition, coimmunoprecipitation of VP2 with anti-NSP5 from extracts of 
infected cells was not observed either (Fig. 26, lane 10), in agreement with previous 
reports (1). 
 
FIG. 26: Analysis of coimmunoprecipitation of VP2 and NSP5. Western blot analysis of cellular 
extracts (lanes 1-8, DSP cross-linked in lanes 1-5 and 17-18, and non-cross-linked in lanes 6-8) 
and immunoprecipitates with anti-NSP5 (lanes 9-16, DSP cross-linked in lanes 9-13 and non-cross-
linked in lanes 14-16) or anti-VP2 (lanes 19-20, DSP cross-linked) derived from cells infected with 







Since tag-VP1 was found in VLS(VP2i) (Fig. 22B), we performed 
coimmunoprecipitation assays from extracts of DSP cross-linked cells coexpressing 
tag-VP1, VP2 and NSP5. We observed that anti-NSP5 and anti-tag antibodies 
were still able to coimmunoprecipitate tag-VP1 and NSP5, respectively, while 
VP2 was not coimmunoprecipitated (Fig. 27, lanes  8, 12). In contrast, a faint 
band of coimmunoprecipitated VP2 was detected for extracts containing only 
NSP5 and VP2 (Fig. 27, lane 6, band indicated by a star). However, this band 
represented a very tiny amount compared to that in the extract, whereas the 
quantities of coimmunoprecipitated tag-VP1 and NSP5 were usually of the same 
order. The anti-VP2 serum was not very efficient in immunoprecipitating significant 
amounts of VP2 and, not surprisingly, did not coimmunoprecipitate any of the two 
other proteins (Fig. 27, lanes 13-16). It has to be noted that the anti-VP2 antibody 
used in this experiment and the anti-VP2 used in experiment of Fig. 26 were 
obtained from different sources. This may explain the different ability to 
immunoprecipitate VP2.  
 
 
 FIG. 27: Analysis of coimmunoprecipitation of NSP5, tag-VP1 and VP2. Western blot analysis of 
extracts (lanes 1-4) and immunoprecipitates with anti-NSP5 (lanes 5-8) or anti-tag (lanes 9-12) or 
anti-VP2 (lanes 13-16) derived from cells cotransfected with various combinations of NSP5, tag-







Finally, since we found that NSP5, NSP2 and VP2 were all present in VLS (Fig. 
17B), we attempted to coimmunoprecipitate them with anti-NSP5 antibody from 
extracts of cells coexpressing all three proteins and DSP cross-linked. We observed 
that VP2 was not coimmunoprecipitated and, surprisingly, NSP2 was not either (Fig. 
28, lane 8), or it was in amounts much smaller than in the absence of VP2 (Fig. 28, 
compare lane 6 with lane 8). More in detail, while in the absence of VP2 the ratio 
between NSP5 and NSP2 was maintained unaltered after coimmunoprecipitation 
(compare lane 2 with lane 6), in its presence it was not and only a faint band of 
coimmunoprecipitated NSP2 was visible (compare lane 4 with lane 8). Tiny amounts 
of coimmunoprecipitated VP2 were observed (lanes 7, 8). The decreased amount of 
coimmunoprecipitated NSP2 in the presence of VP2 might be due either to a 
reduced affinity between NSP5 and NSP2 or, alternatively, to a diminished cross-
linking ability of DSP in the presence of VP2. Under those circumstances, the use of 
DSP would not be helpful, but, on the contrary, be disadvantageous, because DSP 
usually decreases the solubility of NSP5 (see Fig. 8). Therefore, it might cause the 
loss in the insoluble fraction of complexes formed by NSP5, NSP2 and VP2. 
Experiments of comparison between the relative amounts of the coexpressed proteins 
in the soluble and insoluble fractions are under way to evaluate potential artefacts 






FIG. 28: Analysis of coimmunoprecipitation of NSP5, NSP2 and VP2. Western blot analysis of 
extracts (lanes 1-4) and immunoprecipitates with anti-NSP5 (lanes 5-8) derived from cells cotransfected 
with various combinations of NSP5, NSP2 and VP2 plasmids and DSP cross-linked, as indicated. 
 
 
The failure of our attempts of coimmunoprecipitating all viroplasmic components might 
be simply due to methodological limitations (such as conditions of lysis, extraction, 
solubilisation, immunoprecipitation, etc.). However, the results obtained with our 
cotransfection experiments are strengthened by the fact that they are consistent with 
the data published for infected cells: NSP5, NSP2, VP1 and VP2 localize in 
viroplasms (220); NSP2 and VP1, but not VP2, coimmunoprecipitate with NSP5 from 





Rotavirus RNA replication takes place in viroplasms and is mediated by several viral 
proteins, of which the polymerase VP1 and the core protein VP2 are sufficient to 
provide replicase activity in vitro (212, 308). In vivo, however, not well defined viral 
replication complexes are associated with the viroplasm-localised nonstructural 
proteins NSP2 and NSP5. Although the involvement of these two nonstructural 
proteins in the replicative cycle is unquestioned, since silencing their expression 
compromises viroplasm formation, viral genome synthesis and viral progeny 
production, their precise functions remain to be clarified. In this work we aimed at 
clarifying the interactions between NSP5 and the two structural proteins essentially 
required for viral RNA replication, VP1 and VP2. The involvement and the influence 
of other viral proteins in these interactions have also been examined with the aim to 
elucidate the temporal and spatial organization of the events leading to viroplasm 
assembly and synthesis of dsRNA viral genome. 
In the first part of the work, the interaction between NSP5 and the polymerase VP1 
was studied by coimmunoprecipitation and immunofluorescence experiments in both 
virus-infected and cotransfected cells. The capacity of NSP5 to interact with VP1 in 
virus-infected cells had already been observed in coimmunoprecipitation assays from 
DSP cross-linked extracts (2). The same experiments also showed an interaction 
between NSP5 and NSP2, which was subsequently confirmed by other works (85, 
96, 139, 228) and, together with experiments of RNA interference (6, 45, 261) 
and intrabody-mediated silencing (285), led to identify an active role for NSP2 and 
NSP5 in the replication of viral genomic RNA. Because of its enzymatic activities 





properties, NSP2 has been suggested to work as a molecular motor that recruits and 
relaxes ssRNA templates and regulates the homeostasis of the nucleotide pools in 
viroplasms (151, 255, 270, 287). Proposing a role for NSP5, for which an ATPase 
activity was recently reported as its single recognized enzymatic activity (13), is more 
difficult. A structural role in viroplasm formation has been assigned to both 
nonstructural proteins, since in their absence viroplasms are not formed (45, 166, 
261) and their coexpression in uninfected cells leads to the formation of viroplasm-like 
structures (VLS) (96). Here we provide a more detailed description of the nature of the 
interaction of VP1 with NSP5, with NSP2 or with both in the absence of other viral 
proteins or “true” viral RNA [the viral proteins are translated from transcripts of 
plasmids containing only cDNA comprising the coding regions and lacking the 5’ 
and 3’ UTRs (91)] (8). Using extracts of cotransfected MA104 cells, we show by 
coimmunoprecipitation assays that NSP5 has a strong interaction with VP1, which is 
not altered by the presence of NSP2. On the other hand, the interaction of NSP2 
with VP1 appears to be much weaker and possibly stabilized by NSP5 (observed in 
DSP cross-linked extracts). Although it was not formally proven, the formation of a 
ternary complex of VP1, NSP5 and NSP2 is a possibility as tag-VP1 was found in the 
VLS formed as a consequence of the interaction of the two others (Fig. 6). An 
interaction between NSP2 and VP1 in rotavirus-infected cells has been previously 
reported (145). When VP1 was coexpressed with each of the nonstructural proteins 
individually, it became apparent that NSP5 interacted more strongly with VP1 than 
NSP2. However, when the three proteins were coexpressed, NSP5 seemed to 
enhance the interaction of VP1 with NSP2, a conclusion delineated from data using 
DSP cross-linked extracts. Interestingly, several attempted pull down experiments with 





VP1. Thus, it is likely that most of the NSP2 molecules are buried within the cross-
linked complex and therefore not accessible to the precipitating antibody. 
In vivo cross-linking with DSP to stabilise complexes of interacting proteins was 
needed in experiments of coimmunoprecipitation with the anti-NSP5 antiserum, 
possibly because the high affinity hyper-immune polyclonal antibody has a 
dissociating activity. However, DSP must be used carefully, as it increases the 
insolubility of the hyperphosphorylated forms of NSP5 (Fig. 8) and may cause the loss 
of interacting complexes in the insoluble fraction. Differently from the anti-NSP5 
serum, the anti-tag monoclonal antibody, which binds to the N-terminus of tag-VP1, 
allowed efficient coimmunoprecipitation of NSP5 or NSP2 or both from extracts that 
have not been cross-linked (Fig. 7). 
Using NSP5 deletion mutants, we found that deletion of the N-terminal 33 amino 
acid region from NSP5 did not affect binding to VP1 while deletion of the last 18 
amino acids from the C-terminus substantially reduced the interaction (Fig. 9) and 
deletion of the last 48 amino acids completely abolished it (Fig. 11). Also, results 
with single domain EGFP fusion chimeras allowed us to identify the 48 amino acids 
at the C-terminus as those involved in the interaction with VP1 (Fig. 10). As the last 
18 C-terminal amino acids of NSP5 have previously been found to be involved in 
dimerisation (279), our data suggest that dimeric NSP5 is better suited for interaction, 
and that the binding region is located just upstream of the C-terminal tail. The region 
of VP1 interacting with NSP5 remains to be defined, but we found that the removal 
of the C-terminal 15 amino acids from tag-VP1 weakens the interaction with NSP5 
(Fig. 12), suggesting an involvement of the C-terminus of VP1. Since the C-terminal 
15 amino acids in the VP1 structure form an α-helical plug that reduces the diameter 





communication), NSP5 might have a role in moving the plug affecting the production 
of viral genome segments. 
Some of the results of this work were obtained by using a VP1 derivative in which the 
12 amino acid long SV5 tag was fused to the N-terminus of VP1. The presence of 
the terminal tag allowed to recognize VP1 by immunoprecipitation or 
immunofluorescence assays. It also allowed us to overcome the problem of only 
having a poorly reactive antibody against the wild-type protein. The polyclonal 
antiserum against VP1 did not react in immunoprecipitation nor in 
immunofluorescence experiments, but only in Western blots. It is possible that the 
antibody, which was made against the N-terminal 435 amino acids, did not 
recognize the folded full-length VP1 protein while it was able to react with the 
denatured protein in Western blots. By contrast, the availability of a potent anti-tag 
monoclonal antibody allowed to study the interaction of VP1 with NSP5 and NSP2. 
In doing so, it had to be considered that fusing tags to a protein may modify its 
structural and functional properties and may lead to artefacts and misinterpretations 
(44). Therefore, in order to ensure the validity of using a tagged version of VP1, we 
analyzed the behaviour of such a protein in the context of viral infection by 
immunofluorescence and analysis of purified viral particles. We found that tag-VP1 
was localized in viroplasms and VLS (Figs. 5, 6) and also packaged into viral 
progeny (Fig. 4). The incorporation efficiency was not high, but unequivocal and 
reproducible. Thus, only a few among the 12 molecules of the VP1 polymerase per 
viral particle (234) would be represented by the tagged VP1. The degree of tag-VP1 
packaging was variable, possibly depending on the relative ratios of infectious units 
of vaccinia virus (used to express the T7 RNA polymerase that in turn transcribes 
transfected genes cloned under the control of the T7 promoter) and rotavirus, as well 





VP1 to TLPs was ruled out by EDTA treatment of TLPs, which did not remove tag-VP1 
(Fig. 4), and also by mixing TLPs with extracts containing an excess of tag-VP1, not 
leading to an association of these two components (results not shown). Succeeding in 
packaging tag-VP1 strengthens the results obtained in this work and represents a 
technical novelty. The system mainly used so far to study interactions among the 
structural proteins and their role in rotavirus morphogenesis (49, 63, 153, 249) is 
based on the coexpression of various combinations of structural proteins or derivatives 
thereof from baculovirus vectors in insect cells to form so-called virus-like particles 
(VLPs). Although VLPs have the structural characteristics and some of the functional 
properties of rotavirus particles (308), their assembly occurs outside the context of 
natural infection. The data provided here demonstrate that the incorporation of the 
exogenous protein into viral particles can take place during natural infection, 
indicating new possibilities for studying viral morphogenesis. While the improvement 
of an already developed reverse genetics system (149, 150) and the development of 
new ones are under investigation, inserting recombinant proteins into progeny 
particles during natural viral infection could help to further define the roles of viral 
proteins. 
It has been reported that NSP5 interacts with VP2 based on two observations: (i) the 
coimmunoprecipitation of VP2 with an anti-NSP5 monoclonal antibody from extracts 
of either virus-infected MA104 cells or insect cells expressing recombinant NSP5 and 
VP2 from baculovirus recombinants; (ii) the pull down of either rotavirus cores or 
purified VLPs containing VP2 using a recombinant GST tagged derivative of NSP5 
expressed in bacteria, purified and bound to glutathione-agarose beads (23). 
However, we found that NSP5 and VP2 were unable to coimmunoprecipitate either 
from infected cells or when coexpressed in uninfected cells, using extracts which had 





hyperphosphorylation was considerably increased following coexpression with VP2 in 
uninfected cells (Figs. 19, 20, 23, 26, 27, 28). We proved that the migration of 
NSP5 bands with apparent higher molecular weight (28-34KDa) was due to the 
addition of phosphates: both in vitro treatment of anti-NSP5 immunoprecipitates with 
lambda-phosphatase and in vivo coexpression of NSP5 and VP2 with the catalitic 
subunit of the cellular phosphatase PP2A (Fig. 19) supported this conclusion, as in 
both cases a disappearance (with λ-phosphatase) or a strong reduction (with PP2A) 
of the NSP5 forms larger than 26KDa were observed. The increase of NSP5 
hyperphosphorylation by VP2 represents a novel finding, which requires further 
analysis. At present, we have only ruled out an exclusive involvement of kinase CK1α 
by using an siRNA directed to this kinase in cells cotransfected with NSP5 and VP2 
genes (Fig. 20). Since CK1α was recently shown to be involved in NSP5 
phosphorylation in infected cells (43), our data confirm that different kinases and 
phosphatases participate in determining the phosphorylation status of NSP5 in the 
context of viral infection.  
Following coexpression of VP1 either with NSP5 and NSP2 or with NSP5 and VP2 
in uninfected cells, we observed a clear reduction in hyperphosphorylation of NSP5 
(Figs. 8, 22), although the interactions between NSP5 and NSP2 or NSP5 and VP1 
were not altered (Figs. 7, 27). Coimmunoprecipitation experiments from extracts of 
virus-infected cells indicated that both NSP5-NSP2 and NSP5-VP1 interactions occur, 
even when NSP5 hyperphosphorylation is inhibited by RNA interference against 
CK1α (43). While all these data clearly suggest that NSP5 phosphorylation is not 
required for interactions with VP1 and NSP2, at present there are insufficient results 
for a comprehensive interpretation of whether and how NSP5 hyperphosphorylation 
is linked to replication and packaging. With this regard, one open and controversial 





formation. Since (i) the two events have been found to be correlated during the 
course of viral infection (228), (ii) NSP2 behaves as an inducer of both NSP5 
hyperphosphorylation and VLS formation (2, 96), (iii) expression of N-terminally 
tagged derivatives of NSP5 in the absence of any other viral protein results in both 
VLS formation (190) and hyperphosphorylation (44), a cause-effect relationship 
between the two events may be hypothesized. However, several lines of evidence 
suggest that NSP5 hyperphosphorylation cannot trigger viroplasm/VLS formation: (i) 
treatment of cells expressing NSP5 from a transfected gene with inhibitors of cellular 
phosphatases leads to NSP5 hyperphosphorylation, but not to VLS formation (27); (ii) 
NSP5 deletion mutants that are not phosphorylated are recruited into viroplasms of 
infected cells (87); silencing CK1α expression in infected cells blocks NSP5-
hyperphosphorylation, but does not impair the formation of viroplasms, although it 
interferes with their maturation (43). Here we presented data showing that, like 
NSP2, VP2 also behaves as an inducer of both NSP5 hyperphosphorylation and VLS 
formation. As already observed in insect cells (23), coexpression of NSP5 and VP2 
in mammalian cells results in the formation of a small number of spherical structures 
concentrated in a perinuclear area (Figs. 13, 14, 16B, 17A, 18). Based on the 
morphological similarity with VLS formed by NSP5 and NSP2, we named these 
structures VLS as well and in order to distinguish the two kinds of VLS, we chose the 
names VLS(NSP2i) and VLS(VP2i), in which “i” stands for “induced”. While the 
correlation between the NSP5 hyperphosphorylation induced by VP2 and VLS(VP2i) 
formation would suggest once again a direct link between the two events, we found 
further evidence doubting this hypothesis. In fact, four conditions in which the VP2-
mediated NSP5 hyperphosphorylation was inhibited resulted in a normal VLS(VP2i) 
formation: (i) coexpression of NSP5 and VP2 with the catalytic subunit of PP2A (Fig. 





VP2 with NSP5 point mutants that cannot undergo hyperphosphorylation (Fig. 23); 
(iv) coexpression of VP2 and NSP5 at the ratio 1:10, which does not lead to NSP5 
hyperphosphorylation (Fig. 24). Therefore, NSP5 hyperphosphorylation is unlikely to 
be the event triggering VLS formation. The C-terminus of NSP5, in particular the last 
18 amino acids, were shown to be required for VLS formation and recruitment of 
NSP5 deletion mutants into viroplasms (85, 87) and for initiating the cascade of 
hyperphosphorylation (84). Since the C-terminal 10 amino acids were shown to 
mediate NSP5 multimerization (279), it might be hypothesized that NSP5 needs to 
multimerize either to form VLS/viroplasms or to be hyperphosphorylated. Both NSP2 
and VP2 might promote the multimerization of NSP5 possibly by inducing a 
conformational change that renders the C-terminus capable of interacting with other 
NSP5 molecules. This multimerization might involve the association of already formed 
dimers of NSP5, as a deletion mutant of NSP5 lacking the C-terminal 10 amino 
acids, and thus the multimerizing region, has been shown to be capable to form 
dimers bound to NSP2 (139) and has been reported to be unable to form 
VLS(NSP2i) (13). According to the proposed model, NSP5 hyperphosphorylation and 
VLS/viroplasm formation would be two concomitant events because of the 
dependence on a common cause, but independent from one another and requiring 
further distinct factors: a serine in position 67 that can be phosphorylated (84) and 
something modifying the NSP5 N-terminus [like a tag (190) or NSP2 (85)]. Such a 
model can explain the often found concurrence of NSP5 hyperphosphorylation and 
VLS/viroplasm formation. In addition, the fact that VP1 induces neither NSP5 
hyperphosphorylation nor VLS formation may be due to its interaction with the C-
terminus of NSP5, which might prevent the NSP5 multimerization. Experiments of 
coexpression of NSP5 and VP1 either with NSP2 or with VP2 revealed that the 





or VP2 (Figs. 7, 27). A favored interaction between NSP5 and VP1 that detracts 
substrate from NSP2 and VP2 might be responsible for the reduced 
hyperphosphorylation of NSP5 in spite of the presence of NSP2 and VP2. However, 
it remains difficult to predict how VP1 is recruited into VLS(NSP2i)  (Figs. 5, 6) and 
VLS(VP2i) (Fig. 22) according to the proposed model. While for understanding the 
localization of VP1 in VLS(VP2i) further data are needed, structural studies on the 
NSP2 octamer allow to propose an explanation for the recruitment into VLS(NSP2i). 
Since NSP2 was shown to be able to bind four dimers of NSP5 (139), it can be 
hypothesized that some sites of the NSP2 octamer bind NSP5-VP1 complexes, whilst 
other sites may bind free NSP5 molecules. These latter ones would have a C-terminus 
available for multimerization with other free NSP5 molecules bound in turn to other 
NSP2 octamers and would allow the formation of VLS(NSP2i) containing VP1. A 
delicate equilibrium between the amounts of NSP5, VP1 and NSP2 molecules 
appears to be required for VLS formation. In this regard, the experiments of 
coexpression of NSP5 with either NSP2 or VP2 in different relative amounts 
suggested that the ratio between the coexpressed proteins is critical for both VLS 
formation and recruitment into VLS: (i) a better recruitment of VP2 into VLS(VP2i) has 
been observed when NSP5 and VP2 plasmids were cotransfected in a ratio 1:10 or 
1:100 (in terms of μg) (Fig. 14); (ii) the fusion protein NSP5-EGFP stably expressed in 
an MA104 stable cell line, which was transiently transfected with a NSP2 expressing 
plasmid, required a supplement of NSP5 transiently expressed to form VLS(NSP2i) 
and to recruit NSP2 into them (Fig. 16C-D); (iii) when the same cell line was 
transiently transfected with the VP2 gene, a supplement of NSP5 was not required for 
VLS(VP2i) formation but for recruitment of VP2 into VLS (Fig. 16A-B). The possibility 
that tagging NSP5 at the C-terminus interfered with VLS formation, as proposed in 





cotransfection of NSP5-EGFP and VP2 plasmids (Fig. 18). The EGFP 
autofluorescence of the fusion protein as a tracer of VLS was validated by 
immunofluorescence assays with anti-NSP5 antibodies on MA104 NSP5-EGFP cells 
cotransfected with wild-type NSP5 and NSP2 or VP2 expressing plasmids, which 
showed a perfect colocalization of NSP5-EGFP and wild-type NSP5 (Figs. 16, 17).  
Among the data presented, some are quite difficult to interpret and require further 
investigations: the difference in number and distribution between VLS(VP2i) and 
VLS(NSP2i); the fact that NSP5 partially dephosphorylated by the catalytic subunit of 
PP2A forms VLS(VP2i) similar in number and distribution to VLS(NSP2i); and above all 
the lack of coimmunoprecipitation of NSP5 and VP2, although both colocalize in VLS 
and although different conditions of cell lysis and immunoprecipitation have been 
tried. In order to widen the information about the interaction between NSP5 and 
VP2, experiments with different kinase inhibitors in infected and cotransfected cells 
will be performed. In addition, a tagged derivative of VP2 fused to a peptide that is 
in vivo biotinylated (236) will be expressed in uninfected cells, with or without 
concomitant expression of NSP5; VP2 will then be purified together with possibly 
interacting cellular partners by streptavidin magnetic beads and the purified material 
will be analyzed by mass spectrometry. 
Coexpression of NSP5 with both VLS-inducers, NSP2 and VP2, provided the 
following evidence: (i) VLS were formed in number and distribution typical of 
VLS(NSP2i) and able to recruit both NSP2 and VP2 (Fig. 17B); (ii) the pattern of 
NSP5 phosphorylation bands was the same as observed in assays of coexpression of 
only NSP5 and VP2 (Fig. 28); (iii) the amount of NSP2 coimmunoprecipitated with 
anti-NSP5 antibodies from DSP cross-linked extracts was reduced compared to the 
amount coimmunoprecipitated in the absence of VP2 (Fig. 28). Several hypotheses 





changes in NSP5 and/or NSP2 or modify their relative positions, compromising the 
capability of DSP to cross-link them. Alternatively, NSP5 molecules which have 
already interacted with VP2 may have a reduced affinity for NSP2. Finally, VP2 
might dislodge NSP5 from NSP2 or vice versa. Finally, since all three proteins were 
found in VLS, it cannot be ruled out that DSP decreases the solubility of ternary 
complexes, which may get lost from the analysis by transfer into the insoluble fraction 
during preparation of cellular extracts. In order to explore this further, experiments of 
comparison of the relative amounts of the coexpressed proteins in the soluble and 
insoluble fractions are under way. Moreover, an interaction between VP2 and NSP2, 
which has never been described before, may be involved and thus it is worth 
investigating. 
From all coexpression experiments presented, NSP5 appears to be the key protein for 
formation of different types of VLS and for recruitment of other viroplasmic proteins. 
Besides NSP2, VP2 and VP1, VP6 has also been found localized in VLS(VP2i) (Fig. 
25). At present, there is no evidence of an interaction between VP6 and NSP5. In 
fact, NSP5 has been reported to dislodge VP6 from VLPs formed in insect cells (23). 
Experiments with siRNAs silencing NSP5 expression in infected cells showed an 
altered distribution of the viroplasmic proteins VP2, NSP2 and VP6, suggesting a role 
for NSP5 in the recruitment of viral proteins into viroplasms (166), in agreement with 
our data. In addition, silencing of NSP4 expression was also shown to cause a 
delocalization of VP6 concomitantly with a decreased expression of NSP5 and 
NSP2 (165). Therefore, it has been proposed that the distribution of VP6 is sensitive 
to the concentration of proteins that accumulate in viroplasms (166). Once again, the 






In conclusion, coexpression of different combinations of viroplasmic proteins can be 
considered a valid strategy to investigate their interactions and be of help towards a 
better understanding of viroplasm assembly. In order to “re-make” viroplasms by 
transfection experiments, the recruitment into VLS of transfected viral RNAs needs to 
be addressed. However, it has been shown that labelled exogenous viral mRNAs 
transfected into rotavirus infected cells do not localize in viroplasms suggesting the 
lack of pathways trafficking plus-strand RNAs from cytosol to viroplasms (261). This 
may represent a limit in “re-making” viroplasms by transfection experiments. However, 
it is encouraging that recombinant viruses of the family Reoviridae have been 
obtained starting from an exclusively plasmid-based system in the case of reoviruses 
(147) or from transfection of a complete set of viral mRNAs in vitro transcribed either 
by viral cores (34) or by the T7 in vitro transcription system (33) in the case of 
Bluetongue Virus.  
In the process of viroplasm assembly also cellular proteins might be involved. It has 
been reported that a functional microtubule network is needed for viroplasm growth, 
presumably through an association of both NSP5 and NSP2 with tubulin (42). 
However, we could never reproduce the interaction with tubulin of the two 
nonstructural rotavirus proteins (Campagna and Burrone, unpublished results). In 
addition, an association between viroplasms and some components of cellular lipid 
storage organelles has recently been found and is under further investigation (Dr. 
Ulrich Desselberger, University of Cambridge, personal communication). The 
discovery of cellular factors interacting with viroplasmic proteins, in conjunction with 
the characterization of the dynamic interactions between the viral proteins found in 






Finally, we propose a model for the first phases of viroplasm formation and genome 
RNA synthesis, where NSP5 would play a key role in forming viroplasms and 
recruiting all the other viroplasmic components (see scheme below). Following viral 
protein translation, NSP5 may be distributed into three pools: 
1. bound to replicase-incompetent precore replication intermediates (RI) (VP1-VP3-
RNA) through interaction of its C-terminus with VP1; this pool would be 
hypophosphorylated and unable to be recruited into viroplasms; 
2. forming “viroplasm precursors” [possibly around DLPs of the incoming infection 
(261)] because of interactions with the newly synthesized VP2 and/or NSP2; 
this pool would be hyperphosphorylated and able to recruit the other 
viroplasmic proteins; 
3. free in cytosol; this pool would be hypophosphorylated. 
Through its multiple binding sites the NSP2 octamer might hook up: 
1. NSP5 bound to precore RI; this association might prevent VP2 binding 
impeding replication to start, as previously proposed (291); 
2. free NSP5; this interaction would trigger the NSP5 multimerization resulting in 
viroplasm formation and recruitment of NSP2 itself and precore RI, as already 
proposed above. 
Once located in viroplasms, NSP2-NSP5-precore RI complexes would lie in a VP2-
rich environment. VP2 might determine a detachment of NSP2 and interact with 
precore RI, which would become consequently replicase-competent RI. Considering 
that NSP5 and RNA were shown to compete for the same binding sites on NSP2 
(139), an impaired NSP5-NSP2 binding because of VP2 might advantage RNA, 
thus allowing NSP2 to exert its enzymatic activities. The hyperphosphorylation of 





phosphoproteins forming the regulatory subunits of polymerases of negative-strand 
RNA viruses (133, 254).  
This model is consistent with the purification of replicase-incompetent precore RI from 
extracts of infected cells (104) and with the coimmunoprecipitation of VP1-NSP5-
NSP2 complexes not containing VP2 (2). Future experiments will test the validity of 
such a model, in which NSP5 would have the dual function of directing the 
architectural assembly of viroplasms and recruiting the other viroplasmic proteins as 
well as the RNA templates via its interaction with VP1 and NSP2. 
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